US20210177775A1 - Method for the treatment of fatty liver disease - Google Patents
Method for the treatment of fatty liver disease Download PDFInfo
- Publication number
- US20210177775A1 US20210177775A1 US17/180,781 US202117180781A US2021177775A1 US 20210177775 A1 US20210177775 A1 US 20210177775A1 US 202117180781 A US202117180781 A US 202117180781A US 2021177775 A1 US2021177775 A1 US 2021177775A1
- Authority
- US
- United States
- Prior art keywords
- group
- compound
- treatment
- fatty liver
- enlargement ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000011282 treatment Methods 0.000 title description 60
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 85
- 208000004930 Fatty Liver Diseases 0.000 claims description 30
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 30
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 21
- 206010016654 Fibrosis Diseases 0.000 claims description 20
- 230000007423 decrease Effects 0.000 claims description 20
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 17
- 239000008103 glucose Substances 0.000 claims description 17
- 241001486992 Taiwanofungus camphoratus Species 0.000 claims description 15
- 230000004761 fibrosis Effects 0.000 claims description 15
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 13
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 13
- 210000005229 liver cell Anatomy 0.000 claims description 12
- 208000018380 Chemical injury Diseases 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 230000007882 cirrhosis Effects 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 4
- -1 cyclohexenone compound Chemical class 0.000 abstract description 19
- 210000004185 liver Anatomy 0.000 description 65
- 238000012360 testing method Methods 0.000 description 45
- 229940125904 compound 1 Drugs 0.000 description 44
- 102000008186 Collagen Human genes 0.000 description 42
- 108010035532 Collagen Proteins 0.000 description 42
- 229920001436 collagen Polymers 0.000 description 42
- 230000008021 deposition Effects 0.000 description 26
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 22
- 108010082126 Alanine transaminase Proteins 0.000 description 22
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 21
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 21
- LJTSIMVOOOLKOL-UHFFFAOYSA-N 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyldodeca-2,6,10-trienyl)cyclohex-2-en-1-one Chemical compound COC1=C(OC)C(=O)C(C)C(CC=C(C)CCC=C(C)CCC=C(C)C)C1O LJTSIMVOOOLKOL-UHFFFAOYSA-N 0.000 description 18
- 239000003981 vehicle Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 15
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 14
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 14
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 14
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 14
- 238000010586 diagram Methods 0.000 description 14
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000008595 infiltration Effects 0.000 description 12
- 238000001764 infiltration Methods 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- LJTSIMVOOOLKOL-JAXLGGSGSA-N antroquinonolTM Natural products COC1=C(OC)C(=O)[C@@H](C)[C@H](CC=C(C)CCC=C(C)CCC=C(C)C)[C@H]1O LJTSIMVOOOLKOL-JAXLGGSGSA-N 0.000 description 11
- 210000000013 bile duct Anatomy 0.000 description 11
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical class O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 210000004969 inflammatory cell Anatomy 0.000 description 10
- 238000013424 sirius red staining Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 9
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000000835 fiber Substances 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 206010067125 Liver injury Diseases 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 7
- 235000009200 high fat diet Nutrition 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 0 *OC1C([Y][2*])=C(C[1*])C(=O)C([3*])C1C/C=C(\C)C[4*] Chemical compound *OC1C([Y][2*])=C(C[1*])C(=O)C([3*])C1C/C=C(\C)C[4*] 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 6
- 231100000753 hepatic injury Toxicity 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 150000002596 lactones Chemical class 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 230000037390 scarring Effects 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000014101 glucose homeostasis Effects 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 238000011374 additional therapy Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CLKKJHWIJFQRRW-UHFFFAOYSA-N 4-hydroxy-2,3-dimethoxy-5-(11-methoxy-3,7,11-trimethyldodeca-2,6-dienyl)-6-methylcyclohex-2-en-1-one Chemical compound COC1=C(OC)C(=O)C(C)C(CC=C(C)CCC=C(C)CCCC(C)(C)OC)C1O CLKKJHWIJFQRRW-UHFFFAOYSA-N 0.000 description 2
- ZYUOTGLGTVKSJN-GIWBLDEGSA-N 4-hydroxy-2,3-dimethoxy-5-(11-methoxy-3,7,11-trimethyldodeca-2,6-dienyl)-6-methylcyclohex-2-enone Natural products CO[C@H]1[C@@H](CC=C(C)CCC=C(C)CCCC(C)(C)OC)[C@@H](C)C(=O)C(=C1OC)OC ZYUOTGLGTVKSJN-GIWBLDEGSA-N 0.000 description 2
- ZWOCHHLELCKWCK-UHFFFAOYSA-N 4-hydroxy-2,3-dimethoxy-6-methylcyclohexa-2,5-dien-1-one Chemical compound COC1=C(OC)C(=O)C(C)=CC1O ZWOCHHLELCKWCK-UHFFFAOYSA-N 0.000 description 2
- WUMLOGXKIKNTPT-UHFFFAOYSA-N 4-hydroxy-5-(11-hydroxy-3,7,11-trimethyldodeca-2,6-dienyl)-2,3-dimethoxy-6-methylcyclohex-2-en-1-one Chemical compound COC1=C(OC)C(=O)C(C)C(CC=C(C)CCC=C(C)CCCC(C)(C)O)C1O WUMLOGXKIKNTPT-UHFFFAOYSA-N 0.000 description 2
- WUMLOGXKIKNTPT-IRFCIJBXSA-N 4-hydroxy-5-(11-hydroxy-3,7,11-trimethyldodeca-2,6-dienyl)-2,3-dimethoxy-6-methylcyclohex-2-enone Natural products COC1=C(OC)C(=O)[C@@H](C)[C@H](CC=C(/C)CCC=C(/C)CCCC(C)(C)O)[C@H]1O WUMLOGXKIKNTPT-IRFCIJBXSA-N 0.000 description 2
- BGCPLWWYPZAURQ-UHFFFAOYSA-N 5-[[5-chloro-2-(2,2,6,6-tetramethylmorpholin-4-yl)pyrimidin-4-yl]amino]-3-(3-hydroxy-3-methylbutyl)-1-methylbenzimidazol-2-one Chemical compound ClC=1C(=NC(=NC=1)N1CC(OC(C1)(C)C)(C)C)NC1=CC2=C(N(C(N2CCC(C)(C)O)=O)C)C=C1 BGCPLWWYPZAURQ-UHFFFAOYSA-N 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- LJTSIMVOOOLKOL-NXGXIAAHSA-N COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(C)C1=O Chemical compound COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(C)C1=O LJTSIMVOOOLKOL-NXGXIAAHSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 241000386927 Cinnamomum micranthum f. kanehirae Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010021518 Impaired gastric emptying Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 201000007981 Reye syndrome Diseases 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- WGCOQYDRMPFAMN-ZDUSSCGKSA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-pyrimidin-5-ylmethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1C=NC=NC=1 WGCOQYDRMPFAMN-ZDUSSCGKSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003510 anti-fibrotic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003150 biochemical marker Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000012754 cardiac puncture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000001610 euglycemic effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000001288 gastroparesis Diseases 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000013427 histology analysis Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical group CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
- RSFQOQOSOMBPEJ-UHFFFAOYSA-N 3-Methyl-2-hexenoic acid Natural products CCC(C)=CC(O)=O RSFQOQOSOMBPEJ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- 241000486679 Antitype Species 0.000 description 1
- LUSZELLFBWUVBI-SFHLNBCPSA-N Antroquinonol B Natural products COC1=C(OC)C(=O)[C@H](C)[C@@H](CC=C(C)CCC=C(C)CC=CC(C)(C)O)[C@H]1O LUSZELLFBWUVBI-SFHLNBCPSA-N 0.000 description 1
- KHLSTGAGUBFXRF-UHFFFAOYSA-N Antroquinonol C Natural products COC1=C(OC)C(=O)C(C)C(CC=C(C)CCC=C(C)CC=CC(C)(C)OC)C1O KHLSTGAGUBFXRF-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 239000011547 Bouin solution Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- HDJSMCGQFIGPFJ-XYXGIBCTSA-N CC(C(C/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CF)C(C(OC)=C1OC)O)C1=O Chemical compound CC(C(C/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CF)C(C(OC)=C1OC)O)C1=O HDJSMCGQFIGPFJ-XYXGIBCTSA-N 0.000 description 1
- PPHJMGFZVVRQRH-XWWDOVJKSA-N CC(C(C/C=C(\C)/CC/C=C(\C)/Cc1ccccc1)C(C(OC)=C1OC)O)C1=O Chemical compound CC(C(C/C=C(\C)/CC/C=C(\C)/Cc1ccccc1)C(C(OC)=C1OC)O)C1=O PPHJMGFZVVRQRH-XWWDOVJKSA-N 0.000 description 1
- BKIYHIYKSUSKFT-GXNPPGSHSA-N CCC(=O)C/C(C)=C/CC1C(C)C(=O)C(SC)=C(OC)C1O.CNC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCCC(C)(C)OC)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CCC2=CC=CC=C2)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CCCO)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CO[C@H]2OC(CO)[C@H](O)C(O)[C@H]2O)C(C)C1=O Chemical compound CCC(=O)C/C(C)=C/CC1C(C)C(=O)C(SC)=C(OC)C1O.CNC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCCC(C)(C)OC)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CCC2=CC=CC=C2)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CCCO)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CO[C@H]2OC(CO)[C@H](O)C(O)[C@H]2O)C(C)C1=O BKIYHIYKSUSKFT-GXNPPGSHSA-N 0.000 description 1
- UONILBRSOOAEAP-FYALJKSVSA-N CCC/C(C)=C/CC1C(C)C(=O)C(SC)=C(OC)C1O.COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)C(C)=O)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CC2CCC(C)C(=O)O2)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CN)C(C)C1=O.COC1=C(OC)[C@H](OC(C)=O)[C@H](C/C=C(\C)CC/C=C(\C)CC2CC(C)C(=O)O2)[C@@H](C)C1=O.[H]C(=O)/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1C(C)C(=O)C(OC)=C(OC)C1O Chemical compound CCC/C(C)=C/CC1C(C)C(=O)C(SC)=C(OC)C1O.COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)C(C)=O)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CC2CCC(C)C(=O)O2)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CN)C(C)C1=O.COC1=C(OC)[C@H](OC(C)=O)[C@H](C/C=C(\C)CC/C=C(\C)CC2CC(C)C(=O)O2)[C@@H](C)C1=O.[H]C(=O)/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1C(C)C(=O)C(OC)=C(OC)C1O UONILBRSOOAEAP-FYALJKSVSA-N 0.000 description 1
- OEVNFNDXOLYQFL-WUKUYCJSSA-N COC1=C(O)C(=O)C(C)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C)C1O.COC1=C(O)C(O)C(C/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCCC(C)(C)O)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CCC(=O)O)C(C)C1=O.COC1=C(SC)C(O)C(C/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(C)C1=O Chemical compound COC1=C(O)C(=O)C(C)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C)C1O.COC1=C(O)C(O)C(C/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCCC(C)(C)O)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CCC(=O)O)C(C)C1=O.COC1=C(SC)C(O)C(C/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(C)C1=O OEVNFNDXOLYQFL-WUKUYCJSSA-N 0.000 description 1
- DYSBFKVJIRHMFN-BWQFEYBBSA-N COC1=C(O)C(O)C(C/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CCC(=O)O)C(C)C1=O Chemical compound COC1=C(O)C(O)C(C/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CCC(=O)O)C(C)C1=O DYSBFKVJIRHMFN-BWQFEYBBSA-N 0.000 description 1
- ZLTFLFCUZANMSK-UHFFFAOYSA-N COC1=C(O)C(O)C(CC=C(C)CCC=C(C)CCC=C(C)C)C(C)C1=O Chemical compound COC1=C(O)C(O)C(CC=C(C)CCC=C(C)CCC=C(C)C)C(C)C1=O ZLTFLFCUZANMSK-UHFFFAOYSA-N 0.000 description 1
- YHOIKKNELCYWGT-CPFMUPCDSA-N COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CF)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CC2=CC=CC=C2)C(C)C1=O Chemical compound COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CF)C(C)C1=O.COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CC2=CC=CC=C2)C(C)C1=O YHOIKKNELCYWGT-CPFMUPCDSA-N 0.000 description 1
- WUMLOGXKIKNTPT-QKXOVSGLSA-N COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCCC(C)(C)O)C(C)C1=O Chemical compound COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCCC(C)(C)O)C(C)C1=O WUMLOGXKIKNTPT-QKXOVSGLSA-N 0.000 description 1
- CLKKJHWIJFQRRW-CBXDKUCNSA-N COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCCC(C)(C)OC)C(C)C1=O Chemical compound COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCCC(C)(C)OC)C(C)C1=O CLKKJHWIJFQRRW-CBXDKUCNSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010061857 Fat necrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241000222383 Polyporales Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- JCGCKSUCGVTMNB-UHFFFAOYSA-N acetic acid;formaldehyde Chemical compound O=C.CC(O)=O JCGCKSUCGVTMNB-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229940126523 co-drug Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000678 effect on lipid Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- DNVPQKQSNYMLRS-APGDWVJJSA-N ergosterol group Chemical group [C@@H]1(CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)\C=C\[C@H](C)C(C)C DNVPQKQSNYMLRS-APGDWVJJSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229940035734 metformin and sulfonylureas Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229940105902 mint extract Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a method for the treatment of fatty liver disease, and more particularly, to a method of administering a cyclohexenone compound.
- Fatty liver refers to a pathogenic condition where fat comprises more than 5% of the total weight of the liver. Fatty liver and steatohepatitis are frequently found in people who intake excessive alcohols and who have obesity, diabetes, hyperlipidemia, etc.
- NAFLD nonalcoholic fatty liver disease
- steatosis simple fatty liver
- NASH nonalcoholic steatohepatitis
- cirrhosis irreversible, advanced scarring of the liver. All of the stages of NAFLD have in common the accumulation of fat (fatty infiltration) in the liver cells (hepatocytes).
- NASH the fat accumulation is associated with varying degrees of inflammation (hepatitis) and scarring (fibrosis) of the liver.
- the NAFLD spectrum is thought to begin with and progress from its simplest stage, called simple fatty liver (steatosis). That is, fatty liver is the initial abnormality in the spectrum of NAFLD. Simple fatty liver involves just the accumulation of fat in the liver cells with no inflammation or scarring. The fat is actually composed of a particular type of fat (triglyceride) that accumulates within the liver cells. Fatty liver is a harmless (benign) condition.
- the next stage and degree of severity in the NAFLD spectrum is NASH. As mentioned, NASH involves the accumulation of fat in the liver cells as well as inflammation of the liver.
- the inflammatory cells can destroy the liver cells (hepatocellular necrosis).
- steatohepatitis and “steatonecrosis”
- steato refers to fatty infiltration
- hepatitis refers to inflammation in the liver
- necrosis refers to destroyed liver cells.
- NASH in contrast to simple fatty liver, is not a harmless condition. This means that NASH can ultimately lead to scarring of the liver (fibrosis) and then irreversible, advanced scarring (cirrhosis). Cirrhosis that is caused by NASH is the last and most severe stage in the NAFLD spectrum.
- the invention provides a method of treating, inhibiting and/or preventing fatty liver disease in a patient in need thereof, comprising administering an effective amount of a cyclohexenone compound of the formula (I) as described herein to said patient.
- the cyclohexenone compound is administered with a second ingredient.
- a cyclohexenone compound of the following formula (I) in one aspect provides methods of treating, inhibiting and/or preventing fatty liver disease in a patient in need thereof, comprising administering an effective amount of a cyclohexenone compound of the following formula (I) to said patient,
- FIG. 1 shows representative photomicrographs of HE-stained sections of livers of Group A (vehicle control) and Group B (test compound, Compound 1) in a Fatty Liver
- FIG. 1(A) and 1(B) show HE-stained sections of livers of Group A at an enlargement ratio of 50 ⁇ enlargement ratio of 200 ⁇ , respectively.
- FIGS. 1(C) and 1(D) show HE-stained sections of livers of Group B at an enlargement ratio of 50 X enlargement ratio of 200 ⁇ .
- FIG. 2 (A-D) shows representative photomicrographs of Sirius-red stained sections of livers of Group A and Group B Fatty Liver Disease model.
- FIGS. 2(A) and 2(B) show Sirius-red stained sections of livers of Group A at an enlargement ratio of 50 ⁇ enlargement ratio of 200 ⁇ , respectively.
- FIGS. 2(C) and 2(D) show Sirius-red stained sections of livers of Group B at an enlargement ratio of 50 ⁇ enlargement ratio of 200 ⁇ .
- FIG. 3 (A-D) shows representative photomicrographs of collagen Type 3-immunostained sections of livers of Group A and Group B Fatty Liver Disease model.
- FIGS. 3(A) and 3(B) show collagen Type 3-immunostained sections of livers of Group A at an enlargement ratio of 50 ⁇ enlargement ratio of 400 ⁇ , respectively.
- FIGS. 3(C) and 3(D) show Sirius-red stained sections of livers of Group B at an enlargement ratio of 50 ⁇ enlargement ratio of 400 ⁇ .
- FIG. 4 shows diagrams of the whole blood glucose concentration (mg/dL) of Group A and Group B.
- FIG. 5 shows diagrams of the plasma triglyceride concentration (mg/dL) of Group A and Group B.
- FIG. 6 and FIG. 7 respectively show diagrams of plasma AST and plasma ALT concentration (U/dL) of Group A and Group B.
- FIG. 8 (A-D) shows representative photomicrographs of HE-stained sections of livers of Group A and Group B regarding fibrosis of steatohepatitis liver cells.
- FIGS. 8(A) and 8(B) show HE-stained sections of livers of Group A at an enlargement ratio of 50 ⁇ enlargement ratio of 200 ⁇ , respectively.
- FIGS. 8(C) and 8(D) show HE-stained sections of livers of Group B at an enlargement ratio of 50 ⁇ enlargement ratio of 200 ⁇ .
- FIG. 9 (A-D) shows representative photomicrographs of Sirius-red stained sections of livers of Group A and Group B regarding fibrosis of steatohepatitis liver cells.
- FIGS. 9(A) and 9(B) show Sirius-red stained sections of livers of Group A at an enlargement ratio of 50 ⁇ enlargement ratio of 200 ⁇ , respectively.
- FIGS. 9(C) and 9(D) show Sirius-red stained sections of livers of Group B at an enlargement ratio of 50 ⁇ enlargement ratio of 200 ⁇ .
- FIG. 10 (A-D) shows representative photomicrographs of collagen Type 3-immunostained sections of livers of Group A and Group B regarding fibrosis of steatohepatitis liver cells.
- FIGS. 10(A) and 10(B) show collagen Type 3-immunostained sections of livers of Group A at an enlargement ratio of 50 ⁇ enlargement ratio of 400 ⁇ , respectively.
- FIGS. 10(C) and 10(D) show Sirius-red stained sections of livers of Group B at an enlargement ratio of 50 ⁇ enlargement ratio of 400 ⁇ .
- FIG. 11 shows diagrams of the whole blood glucose concentration (mg/dL) of Group A and Group B.
- FIG. 12 shows diagrams of the plasma triglyceride concentration (mg/dL) of Group A and Group B.
- FIG. 13 and FIG. 14 respectively show diagrams of plasma AST and plasma ALT concentration (U/dL) of Group A and Group B.
- FIG. 15 (A-F) shows representative photomicrographs of HE-stained sections of livers in a fatty liver condition assay in Group A (vehicle control), Group B (test compound & ergosterol) and Group C (test compound alone).
- FIGS. 15(A) and 15(B) show HE-stained sections of livers of Group A at an enlargement ratio of 50 ⁇ enlargement ratio of 200 ⁇ , respectively.
- FIGS. 15(C) and 15(D) show HE-stained sections of livers of Group B at an enlargement ratio of 50 ⁇ enlargement ratio of 200 ⁇ .
- FIGS. 15(E) and 15(F) show HE-stained sections of livers of Group C at an enlargement ratio of 50 ⁇ enlargement ratio of 200 ⁇ .
- FIG. 16 (A-F) shows representative photomicrographs of Sirius-red stained of livers from Group A to Group C.
- FIGS. 16(A) and 16(B) show Sirius-red stained sections of livers of Group A at an enlargement ratio of 50 ⁇ enlargement ratio of 200 ⁇ , respectively.
- FIGS. 16(C) and 16(D) show Sirius-red stained sections of livers of Group B at an enlargement ratio of 50 ⁇ enlargement ratio of 200 ⁇ .
- FIGS. 16(E) and 16(F) show Sirius-red stained sections of livers of Group C at an enlargement ratio of 50 ⁇ enlargement ratio of 200 ⁇ .
- FIG. 17 (A-F) shows representative photomicrographs of collagen Type 3-immunostained sections of livers from Group A to Group C.
- FIGS. 17(A) and 17(B) show collagen Type 3-immunostained sections of livers of Group A at an enlargement ratio of 50 ⁇ enlargement ratio of 400 ⁇ , respectively.
- FIGS. 17(C) and 17(D) show Sirius-red stained sections of livers of Group B at an enlargement ratio of 50 ⁇ enlargement ratio of 400 ⁇ .
- FIGS. 17(E) and 17(E) show Sirius-red stained sections of livers of Group C at an enlargement ratio of 50 ⁇ enlargement ratio of 400 ⁇ .
- the invention surprisingly found that cyclohexenone compounds described herein effectively treat, inhibit and/or prevent fatty liver disease.
- a and “an” refer to one or to more than one (i.e., to at least one) of the grammatical object of the article.
- treat means reducing the frequency, extent, severity and/or duration with which symptoms of fatty liver disease are experienced by a patient.
- prevent means inhibition, risk reduction, reducing the onset of or the averting of symptoms associated with fatty liver disease.
- pharmaceutically acceptable salt refers to those salts which retain the biological effectiveness and properties of the free bases and which are obtained by reaction with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, malic acid, maleic acid, succinic acid, tartaric acid, citric acid, and the like.
- inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, malic acid, maleic acid, succinic acid, tartaric acid, citric acid, and the like.
- the term “effective amount” means an amount of the compound described herein effective to treat, inhibit and/or prevent fatty liver diseases.
- the effective amount of the compound described herein reduces the number of fat cells; reduces the liver size; inhibits (i.e., slow to some extent and preferably stop) fatty cell infiltration; inhibits (i.e., slows at least to some extent and preferably stops) inflammation (hepatitis), scarring (cirrhosis) or necrosis; and/or relieves to some extent one or more of the symptoms associated with the disease.
- Antrodia camphorata is also called Chang-Zhi, Niu Chang-Gu, red camphor mushroom and the like, which is a perennial mushroom belonging to the order Aphyllophorales, the family Polyporaceae. It is an endemic species in Taiwan growing on the inner rotten heart wood wall of Cinnamomum kanehirae Hay. C. kanehirai Hay is rarely distributed and being overcut unlawfully, which makes A. camphorata growing inside the tree in the wild became even rare. The price of A. camphorata is very expensive due to the extremely slow growth rate of natural A. camphorata that only grows between Junes to October.
- A. camphorata is used as a Chinese remedy for food, alcohol, and drug intoxication, diarrhea, abdominal pain, hypertension, skin itches, and liver cancer.
- Triterpenoids are the most studied component among the numerous compositions of A. camphorata.
- U.S. Pat. No. 7,385,088 is directed to a novel compound and use thereof, in particular to Antroquinonol B and Antroquinonol C isolated from A. camphorata extracts which effectively inhibit the growth of certain cancer cells.
- U.S. Pat. No. 7,342,137 provides cyclohexenone compounds and their uses in tumor growth inhibition, which is an extract isolated and purified from A. camphorate, in particular to 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone.
- 7,456,225 discloses the use of 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone in liver protection such as alleviating liver injury and fibrosis induced by chemicals and reduces the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
- ALT alanine aminotransferase
- AST aspartate aminotransferase
- U.S. Pat. No. 7,468,392 discloses the use of 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6-10-trienyl)-cyclohex-2-enone in delaying fatigue.
- 7,501,454 relates to the use of 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl-)-cyclohex-2-enone in treating autoimmune diseases.
- US 8,236,860 provides the use of 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone in inhibiting the survival of pancreatic cancer cells.
- US 20110060055, US 20110060056, US 20110060057, US 20110060058 and US 20110060059 disclose the use of 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl-)-cyclohex-2-enone in inhibiting the survival of lymphoma, gastric cancer, skin cancer, ovarian cancer and bladder cancer cells, respectively.
- the invention provides a method of treating, inhibiting and/or preventing fatty liver diseases in a patient in need thereof, comprising administering an effective amount of a cyclohexenone compound of the following formula (I) to said patient,
- each of X and Y independently is oxygen, NR 5 or sulfur;
- R is a hydrogen or C( ⁇ O)C 1 -C 8 alkyl; each of R 1 , R 2 and R 3 independently is a hydrogen, methyl or (CH 2 ) m —CH 3 ;
- R 4 is NR 5 R 6 , OR 5 , OC( ⁇ O)R 7 , C( ⁇ O)OR 5 , C( ⁇ O)R 5 , C( ⁇ O)NR 5 R 6 , halogen, 5 or 6-membered lactone, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, aryl, glucosyl, wherein the 5 or 6-membered lactone, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, aryl, and glucosyl are optionally substituted with one or more substituents selected from NR 5
- the fatty liver diseases are the primary fatty liver diseases or the secondary fatty liver diseases.
- the secondary fatty liver disease is alcohol liver disease, fatty liver associated with chronic hepatitis infection, total parental nutrition (TPN), Reye's Syndrome, gastrointestinal disorders, or gastroparesis and irritable bowel (IBS) disorders.
- the fatty liver disease is cirrhosis or fibrosis.
- the cyclohexenone compound having the following structure
- the cyclohexenone compound is prepared synthetically or semi-synthetically from any suitable starting material.
- the cyclohexenone compound is prepared by fermentation, or the like.
- Compound 1 also known as AntroquinonolTM or “Antroq”
- Compound 3 in some instances, is prepared from 4-hydroxy-2,3-dimethoxy-6-methylcyclohexa-2,5-dienone.
- the non-limited exemplary compounds are illustrated below.
- the organic solvent is selected from alcohols (e.g., methanol, ethanol, propanol, or the like), esters (e.g., methyl acetate, ethyl acetate, or the like), alkanes (e.g., pentane, hexane, heptane, or the like), halogenated alkanes (e.g., chloromethane, chloroethane, chloroform, methylene chloride, or the like), and the like.
- exemplary Compounds 1-7 are isolated from organic solvent extracts.
- the organic solvent is alcohol.
- the alcohol is ethanol.
- the cyclohexenone compound is isolated from the aqueous extracts of A. camphorata.
- R is a hydrogen, C( ⁇ O)C 3 H 8 , C( ⁇ O)C 2 H 5 , or C( ⁇ O)CH 3 .
- R 1 is a hydrogen or methyl.
- R 2 is a hydrogen, methyl, ethyl, propyl, butyl, pentyl or hexyl.
- R 3 is a hydrogen, methyl, ethyl, propyl, butyl, pentyl or hexyl.
- R 4 is halogen, NH 2 , NHCH 3 , N(CH 3 ) 2 , OCH 3 , OC 2 H 5 , C( ⁇ O)CH 3 , C( ⁇ O)C 2 H 5 , C( ⁇ O)OCH 3 , C( ⁇ O)OC 2 H 5 , C( ⁇ O)NHCH 3 , C( ⁇ O)NHC 2 H 5 , C( ⁇ O)NH 2 , OC( ⁇ O)CH 3 , OC( ⁇ O)C 2 H 5 , OC( ⁇ O)OCH 3 , OC( ⁇ O)OC 2 H 5 , OC( ⁇ O)NHCH 3 , OC( ⁇ O)NHC 2 H 5 , or OC( ⁇ O)NH 2 .
- R 4 is C 2 H 5 C(CH 3 ) 2 OH, C 2 H 5 C(CH 3 ) 2 OCH 3 , CH 2 COOH, C 2 H 5 COOH, CH 2 OH, C 2 H 5 OH, CH 2 Ph, C 2 H 5 Ph, CH 2 CH ⁇ C(CH 3 )(CHO), CH 2 CH ⁇ C(CH 3 )(C( ⁇ O)CH 3 ), 5 or 6-membered lactone, C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, aryl, and glucosyl, wherein the 5 or 6-membered lactone, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, aryl, and glucosyl are optionally substituted with one or more substituents selected from NR 5 R 6 , OR 5 , OC( ⁇ O)R 7 , C( ⁇ O)OR 5 , C( ⁇ O)
- the compounds provided herein are used in the treatment, inhibition and/or prevention of fatty liver disease.
- fatty liver diseases or liver disorders include the primary fatty liver diseases NAFLD and NASH and the secondary fatty liver diseases (e.g., alcoholic liver disease (ALD), fatty liver associated with chronic hepatitis infection, total parental nutrition (TPN), Reye's Syndrome, and gastrointestinal disorders such as Intestinal Bacterial Overgrowth (IBO), gastroparesis, irritable bowel (IBS) disorders, and the like).
- ALD alcoholic liver disease
- TPN total parental nutrition
- Reye's Syndrome e.g., Reye's Syndrome
- gastrointestinal disorders such as Intestinal Bacterial Overgrowth (IBO), gastroparesis, irritable bowel (IBS) disorders, and the like.
- therapeutically-effective dosages vary when the drugs are used in treatment combinations.
- Combination treatment further includes periodic treatments that start and stop at various times to assist with the clinical management of the patient.
- dosages of the co-administered compounds vary depending on the type of co-drug employed, on the specific drug employed, on the disease, disorder, or condition being treated and so forth.
- the dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is sought is modified in accordance with a variety of factors. These factors include the disorder from which the subject suffers, as well as the age, weight, sex, diet, and medical condition of the subject. Thus, in other embodiments, the dosage regimen actually employed varies widely and therefore deviates from the dosage regimens set forth herein.
- fatty liver disease therapeutic agents include, but are not limited to, the following: ergosterol, vitamin E, selenium, betaine, insulin sensitizers (e.g., Metformin, Pioglitazone, Rosiglitazone, Thiazolidinediones, or the like), and statins, or the like.
- the combinations of the cyclohexenone compounds and other fatty liver disease therapeutic agents described herein encompass additional therapies and treatment regimens with other agents in some embodiments.
- Such additional therapies and treatment regimens include another fatty liver disease therapy in some embodiments.
- additional therapies and treatment regimens include other agents used to treat adjunct conditions associated with fatty liver disease or a side effect from such agent in the combination therapy.
- adjuvants or enhancers are administered with a combination therapy described herein.
- the cyclohexenone compound of the invention is administered with a second ingredient.
- the second ingredient is ergosterol.
- the amounts of the cyclohexenone compound in combination with ergosterol range from 50% (w/w) to 90% (w/w) and 50% (w/w) to 10% (w/w), respectively.
- the compositions described herein and, in embodiments where combinational therapy is employed based on the mode of action described herein other agents do not have to be administered in the same pharmaceutical composition, and in some embodiments, because of different physical and chemical characteristics, are administered by different routes.
- the initial administration is made according to established protocols, and then, based upon the observed effects, the dosage, modes of administration and times of administration is modified by the skilled clinician.
- the compounds provided herein are administered by any convenient route, including oral, parenteral, subcutaneous, intravenous, intramuscular, intra peritoneal, or transdermal.
- the dosage administered depends upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, and the nature of the effect desired.
- the compounds provided herein are mixed with one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations which are used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- the compounds provided herein are formulated as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the compound of the invention; as a powder or granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
- the compounds provided herein are formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer.
- physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants for example polyethylene glycol, are generally known in the art.
- pharmaceutical compositions which are used orally include push-fit capsules.
- the molecules for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
- the dosage unit is determined by providing a valve to deliver a metered amount in some embodiments.
- the dose will be determined by the activity of the compound produced and the condition of the subject, as well as the body weight or surface area of the subject to be treated.
- the size of the dose and the dosing regiment also will be determined by the existence, nature, and extent of any adverse side effects that accompany the administration of a particular compound in a particular subject.
- the physician In determining the effective amount of the compound to be administered, the physician needs to evaluate circulating plasma levels, toxicity, and progression of the disease.
- the HPLC was performed using a RP18 column, methanol (A) and 0.1 ⁇ 0.5% acetic acid (B) as the mobile phase, with gradient of 0 ⁇ 10 min in 95% ⁇ 20% B, 10-20 min in 20% ⁇ 10% B, 20 ⁇ 35 min in 10% ⁇ 10% B, 35-40 min in 10% ⁇ 95% B, at a flow rate of 1 ml/min.
- the effluent was monitored with a UV-visible detector.
- Compound 5 4-hydroxy-5-(11-hydroxy-3,7,11-trimethyldodeca-2,6-dienyl)-2,3-dimethoxy-6-methylcyclohex-2-enone
- Compound 7 4-hydroxy-2,3-dimethoxy-5-(11-methoxy-3,7,11-trimethyldodeca-2,6-dienyl)-6-methylcyclohex-2-enone
- Compound 6 a metabolite of Compound 1, was obtained from urine samples of rats fed with Compound 1 in the animal study.
- Compound 6 was determined to be 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3-methyl-2-hexenoic acid)cyclohex-2-enone with molecular weight of 312 (C 16 H 24 O 6 ).
- Compound 4 which was determined as 3,4-dihydroxy-2-methoxy-6-methyl-5-(3,7,11-trimethyldodeca-2,6,10-trienyl)cyclohex-2-enone (molecular weight of 376, C 23 H 36 O 4 ), was obtained when Compound 1 was under the condition of above 40 ° C. for 6 hours.
- the exemplary compounds may be prepared from 4-hydroxy-2,3-dimethoxy-6-methylcyclohexa-2,5-dienone, or the like.
- the example constructs an animal model using rats fed a high fat diet to evaluate the effects of chronic liver injury. Thereafter, the effects can be revealed through biochemical assays to prove the fatty liver reduction of exemplary compounds provided herein such as Compound 1, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6-10-trienyl)-cyclohex-2-enone (the test compound).
- the assay simulates liver disease caused by a high fat diet through a “Metabolic Syndrome” model. That is, the model is different from conventional chemical induced models caused by toxic components such as CCl 4 . This model is distinguishable from the models caused by virus or alcohol.
- mice were obtained from Charles River Laboratories Japan (Kanagawa, Japan). Animals were housed under specific-pathogen-free (SPF) conditions. The liver injury was developed in 18 male mice by subcutaneous injection of Streptozotocin (STZ) 2 days after birth (day 2). After 4 weeks, a high-fat commercial rodent diet ad libitum (CLEA JAPAN) were supplied. These mice were randomized into 3 groups before the treatment. The test compound was administered in a volume of 10 ml/kg twice a day for three weeks. In the control group (group A), six rats were fed with vehicle (corn oil from Sigma Chemical Co.) via intubation. Six mice in group B were orally administered vehicle and the test compound at a dose of 48 mg/kg twice a day (96 mg/kg per day). Table 1 summarizes the study timetable.
- Table 2 summarizes the treatment schedule.
- HE Staining The HE staining method is performed as follows: Liver slices are cut from the livers' left side, embedded in Tissue-Tek® OCTTM Compounds (Sakura Finetek, Japan), snap frozen in liquid nitrogen, and stored at ⁇ 80° C. 5 ⁇ m sections are cut, air-dried, fixed in acetone, air dried again and finally washed with phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- liver sections will be prefixed in a Bouin solution (formalin-acetic acid) for one week and then stained with Lillie-Mayer's Hematoxylin (Muto Pure Chemicals, Japan) and eosin solution (Wako, Japan) to visualize the lipid deposition, inflammations, cell necrosis and fibrosis, or stained with Masson's trichromic solution to visualize extra cellular matrix and collagen fibers of liver fibrosis development.
- Bouin solution formalin-acetic acid
- the Sirius Red staining method is performed as follows: Liver slices are cut from the livers' left side, embedded in Tissue-Tek® OCTTM Compounds (Sakura Finetek, Japan), snap frozen in liquid nitrogen, and stored at ⁇ 80° C. 5 ⁇ m sections are cut, air-dried, fixed in acetone, air dried again and finally washed with phosphate buffered saline (PBS). Then, liver sections are stained with a Picro-Sirius Red Solution (Waldeck GmbH & KG, Germany) to observe collagen deposition.
- PBS phosphate buffered saline
- AST Plasma Aspartate aminotransferase
- ALT Alanine aminotransferase
- Plasma samples were collected in heparinized syringes (Novo-Heparin 5,000 units/5 ml, Mochida Pharmaceutical, Japan) by cardiac puncture and kept on ice then centrifuged at 1,000 ⁇ g at 4° C. for 15 minutes. The supernatant was collected and stored at ⁇ 80° C. until use.
- AST, ALT levels were measured by FUJI DRY CHEM 7000 (Fuji Film, Japan).
- FIG. 1 to FIG. 7 have proved that the exemplary compound extracted from A. camphorata (Compound 1) effectively decreases the extent of fatty liver disease caused by non-chemical injury.
- the decrease is assessed by evaluating the extent of liver injuries of fat deposition by histological analyses such as HE staining, Sirius red staining and collagen immunostaining, and further by plasma biochemical marker such as blood glucose, plasma triglyceride, plasma ALT and plasma AST.
- FIG. 1 (A-D) shows the representative photomicrographs of HE-stained sections of livers of Group A and Group B, wherein FIG. 1(A) and 1(C) show an enlargement ratio of 50 ⁇ and FIGS. 1(B) and 1(D) show an enlargement ratio of 200 ⁇ .
- the Group A (vehicle) diagrams revealed infiltration of inflammatory cells, macro- and micro vesicular fat deposition, proliferated bile ducts and hepato-cellular ballooning in the liver sections.
- group B the test compound, Compound 1 treatment tended to decrease the infiltration of inflammatory cells and also tended to decrease the macro-vesicular fat deposition compared to Group A.
- FIG. 2 shows the representative photomicrographs of Sirius-red staining of livers of Group A and Group B, wherein FIGS. 2(A) and 2(C) show an enlargement ratio of 50 ⁇ and FIGS. 2(B) and 2(D) show an enlargement ratio of 200 ⁇ .
- Sirius red staining demonstrates collagen deposition around central veins, bile ducts and degenerative hepatocytes.
- FIGS. 2(C) and 2(D) in Group B (the test compound, Compound 1) treatment, the collagen deposition around the central veins and the bile ducts was reduced.
- FIG. 3 shows the representative photomicrographs of collagen Type 3-immunostained sections of livers of Group A and Group B, wherein FIGS. 3(A) and 3(C) show an enlargement ratio of 50 ⁇ and FIGS. 3(B) and 3(D) show an enlargement ratio of 400 ⁇ .
- Collagen Type 3 staining shows accumulation of collagen fibers in the sinusoidal area and around bile ducts and central veins in the Vehicle control group A.
- the Group B the test compound, Compound 1 treatment tended to reduce the thickness and/or the length of the collagen fibers in the sinusoidal area.
- FIG. 4 shows the diagram of the whole blood glucose concentration (mg/dL) of Group A and Group B.
- Group B treatment the test compound, Compound 1
- Group A 636 ⁇ 137 mg/dL
- Group B 580 ⁇ 122 mg/dL
- FIG. 5 shows the diagram of the plasma triglyceride (TG) concentration (mg/dL) of Group A and Group B.
- TG plasma triglyceride
- AST and ALT are important enzymes in the amino acid synthesis for the human organs such as liver, heart, muscles, etc.
- AST and ALT are commonly measured clinically as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. These enzymes' content in serum is low under normal conditions. Significantly elevated levels of AST and ALT often suggest the existence of liver injury.
- FIG. 6 and FIG. 7 show diagrams of plasma AST and plasma ALT concentration (U/dL) for Group A and Group B, respectively. As shown in FIG.
- Group B (the test compound, Compound 1) treatment seems to slightly reduce the plasma AST level compared to Group A (vehicle) treatment (Group A: 202 ⁇ 177 U/L, Group B: 141 ⁇ 35 U/L).
- Group B (the test compound, Compound 1) treatment seems to slightly reduce the plasma ALT level compared to Group A (vehicle) treatment (Group A: 64 ⁇ 64 U/L, Group B: 34 ⁇ 10 U/L).
- test compound treatment decreased the plasma TG levels, tending to inhibit blood glucose levels, and slightly decreased the plasma AST and ALT.
- the test compound treatment also decreased the infiltration of inflammatory cells and fat deposition in the liver lobule.
- the test compound tended to inhibit collagen deposition, shown in both Sirius red staining and collagen Type 3 staining, suggesting that the test compound has an anti-fibrotic effect on liver fibrosis steatohepatitis.
- FIG. 8 to FIG. 14 show that the test compound, Compound 1 effectively decrease fibrosis of steatohepatitis liver cells induced by non-chemical injury.
- the decrease is assessed by evaluating the extent of liver injuries in liver fibrosis by histological analyses such as HE staining, Sirius red staining and collagen immunostaining, and further by plasma biochemical marker such as blood glucose, plasma alanine aminotransferase and plasma aspartate aminotransferase.
- FIG. 8 shows the representative photomicrographs of HE-stained sections of livers of Group A and Group B, wherein FIGS. 8(A) and 8(C) show an enlargement ratio of 50 ⁇ , and FIGS. 8(B) and 8(D) show an enlargement ratio of 200 ⁇ .
- the Group A (vehicle) diagrams reveal infiltration of inflammatory cells, macro- and micro vesicular fat deposition, proliferated bile ducts, and hepatocellular ballooning in the liver sections.
- group B the test compound, Compound 1 treatment tended to decrease the macro-vesicular fat deposition compared to Group A.
- FIG. 9 shows the representative photomicrographs of Sirius-red staining of livers of Group A and Group B, wherein FIGS. 9(A) and 9(C) show an enlargement ratio of 50 ⁇ , and FIGS. 9(B) and 9(D) show an enlargement ratio of 200 ⁇ .
- FIGS. 9(A) and 9(B) in Group A, Sirius red staining demonstrates collagen deposition around central veins, bile ducts and degenerative hepatocytes.
- Group A treatment central-to-central bridging fibrosis is observed, showing serious fibrosis in liver cells.
- FIGS. 9(C) and 9(D) in Group B (the test compound, Compound 1) treatment, the collagen deposition around the central veins and the bile ducts was reduced.
- FIG. 10 shows the representative photomicrographs of collagen Type 3-immunostained sections of livers of Group A and Group B, wherein FIGS. 10(A) and 10(C) show an enlargement ratio of 50 ⁇ , and FIGS. 10(B) and 10(D) show an enlargement ratio of 400 ⁇ .
- Collagen Type 3 staining shows accumulation of collagen fibers in the sinusoidal area, and around bile ducts and central veins in the Vehicle control Group A.
- the Group B the test compound, Compound 1 treatment tended to reduce the thickness and/or the length of the collagen fibers in the sinusoidal area.
- FIG. 11 shows the diagram of the whole blood glucose concentration (mg/dL) of Group A and Group B.
- Group B treatment the test compound, Compound 1
- Group A 728 ⁇ 109 mg/dL
- Group B 566 ⁇ 65 mg/dL
- FIG. 12 shows the diagram of the plasma triglyceride (TG) concentration (mg/dL) of Group A and Group B.
- TG plasma triglyceride
- FIG. 13 and FIG. 14 respectively show diagrams of plasma AST and plasma ALT concentration (U/dL) for Group A and Group B.
- Group B the test compound, Compound 1 treatment slightly increase the plasma AST level compared to Group A (vehicle) treatment, but the change is not significant (Group A: 143 ⁇ 42 U/L, Group B: 167 ⁇ 87 U/L).
- Group B the test compound, Compound 1 treatment reduces the plasma ALT level compared to Group A (vehicle) treatment (Group A: 47 ⁇ 22 U/L, Group B: 38 ⁇ 11 U/L).
- the treatment with the test compound decreased the blood glucose levels, the plasma TG levels, and tends to decrease the fat deposition in the liver lobule and the ALT levels, suggesting that the cyclohexenone compounds provided herein have an ameliorating effect on lipid and carbohydrate metabolism and a protective effect on liver injury caused by a high-fat diet.
- the exemplary cyclohexenone compound e.g., Compound 1 tended to inhibit collagen deposition, shown in both Sims red staining and collagen Type 3 staining, showing that the cyclohexenone compounds provided herein have an anti-fibrotic effect on liver steatohepatitis.
- test compound treatment effectively decrease the extents of fatty liver disease and liver fibrosis induced by metabolic syndrome, especially from high-fat diet treatment.
- Example 3 Reduction of Fatty Liver Condition by the Composition Comprising Compound 1 and Ergosterol
- control group (group A), six rats were fed with vehicle (corn oil from Sigma chemical co.) by means of stomach tubes.
- Six rats in group B were orally administered vehicle and the test compound (Compound 1) at a dose of 48 mg/kg twice a day (96 mg/kg per day) and ergosterol at a dose of 12 mg/kg twice a day (24 mg/kg per day).
- Six mice in group C were orally administered vehicle and the test compound (Compound 1) at a dose of 48 mg/kg twice a day (96 mg/kg per day).
- Table 1 below shows the study timetable summary.
- Table 2 shows the treatment schedule.
- FIG. 15 shows the representative photomicrographs of HE-stained sections of livers from Group A to Group C, wherein FIGS. 15(A), 15(C), 15(E) show an enlargement ratio of 50 ⁇ and FIGS. 15(B), 15(D), 15(F) show an enlargement ratio of 200 ⁇ .
- FIGS. 15(A) and 15(B) the Group A figures revealed infiltration of inflammatory cells, macro- and micro vesicular fat deposition, proliferated bile ducts and hepatocellular ballooning in the liver sections. As shown in FIGS.
- treatment with combination of the test compound (Compound 1) and ergosterol decreased the macro vesicular fat deposition and the infiltration of inflammatory cells.
- the number of mitotic figures in hepatocytes is higher in group B compared to the group A.
- the treatment with the test compound alone tended to decrease the macro vesicular fat deposition but did not affect the infiltration of inflammatory cells.
- FIG. 16 shows the representative photomicrographs of Sirius-red stained of livers from Group A to Group C, wherein FIGS. 16(A), 16(C), 16(E) show an enlargement ratio of 50 ⁇ and FIGS. 16(B), 16(D), 16(F) show an enlargement ratio of 200 ⁇ .
- FIGS. 16(A) and 16(B) in group A, Sirius red staining show collagen deposition around central veins, bile ducts and degenerative hepatocytes, showing central-to-central bridging fibrosis and indicating serious fibrosis steatohepatitis.
- FIGS. 16 shows the representative photomicrographs of Sirius-red stained of livers from Group A to Group C, wherein FIGS. 16(A), 16(C), 16(E) show an enlargement ratio of 50 ⁇ and FIGS. 16(B), 16(D), 16(F) show an enlargement ratio of 200 ⁇ .
- Sirius red staining show collagen deposition around central veins,
- both the treatments with the cyclohexeone compound provided herein (e.g., Compound 1) and ergosterol treatment (Group B) and the treatment with the test compound alone (Group C) tend to inhibit collagen deposition, and thus prevent liver fibrosis. More specifically, the treatment with the combination of the cyclohexenone compound provided herein (e.g., Compound 1) and ergosterol provides a better anti-liver-fibrosis ability compared to the treatment with the test compound alone.
- FIG. 17 shows the representative photomicrographs of collagen Type 3-immunostained sections of livers from Group A to Group C, wherein FIGS. 17(A), 17(C), 17(E) show an enlargement ratio of 100 ⁇ and FIGS. 17(B), 17(D), 17(F) show an enlargement ratio of 400 ⁇ .
- Collagen Type 3 staining shows accumulation of collagen fibers in the sinusoidal area and around bile ducts and central veins in the Vehicle control group.
- FIGS. 17 shows the representative photomicrographs of collagen Type 3-immunostained sections of livers from Group A to Group C, wherein FIGS. 17(A), 17(C), 17(E) show an enlargement ratio of 100 ⁇ and FIGS. 17(B), 17(D), 17(F) show an enlargement ratio of 400 ⁇ .
- Collagen Type 3 staining shows accumulation of collagen fibers in the sinusoidal area and around bile ducts and central veins in the Vehicle control group.
- Example 4 Study of Compound 1 in Patients With Diabetes and Presumed NAFLD
- the primary objectives of this study are to assess, in patients with Type 2 diabetes mellitus (DM) and presumed nonalcoholic fatty liver disease (NAFLD), the following:
- the primary objective of assessing changes in insulin resistance and glucose homeostasis will be attained by performing a euglycemic clamp procedure at baseline (Day 0) and at the end of 6 weeks of treatment (Day 43).
- Hepatocellular function as measured by assessment of liver enzymes and biochemical markers of hepatic and metabolic function
- Active Comparator Drug: Compound 1 50 mg Compound 1 50 mg by mouth once daily, 100 mg by mouth once daily Active Comparator: Drug: Compound 1 100 mg Compound 1 100 mg by mouth once daily, 200 mg by mouth once daily Placebo Comparator: Placebo Drug: Placebo Placebo
- the primary objective of assessing changes in insulin resistance and glucose homeostasis will be attained by performing a euglycemic clamp procedure at baseline (Day 0) and at the end of 6 weeks of treatment (Day 43). Other endpoints will be evaluated by monitoring adverse experiences; vital signs; clinical laboratory values; plasma drug and metabolite concentrations; and general health and well-being.
- Type 2 diabetes defined by the American Diabetes Association (ADA), as one of the following criteria:
- GTT oral glucose tolerance test
- Presumed NAFLD defined by one of the following criteria:
- ALT Alanine aminotransferase
- AST Aspartate aminotransferase
- ALT >155 U/L for females and >185 U/L for males.
- AST >155 U/L for females and >200 U/L for males.
- a pharmaceutical composition for oral delivery 100 mg of an exemplary Compound 1 is mixed with 100 mg of corn oil. The mixture is incorporated into an oral dosage unit in a capsule, which is suitable for oral administration.
- 100 mg of a compound described herein is mixed with 750 mg of starch.
- the mixture is incorporated into an oral dosage unit for, such as a hard gelatin capsule, which is suitable for oral administration.
- a pharmaceutical composition for buccal delivery such as a hard lozenge
- a pharmaceutical composition for buccal delivery such as a hard lozenge
- the mixture is gently blended and poured into a mold to form a lozenge suitable for buccal administration.
- a pharmaceutical composition for inhalation delivery 20 mg of a compound described herein is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is incorporated into an inhalation delivery unit, such as a nebulizer, which is suitable for inhalation administration.
- an inhalation delivery unit such as a nebulizer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
- The present invention relates to a method for the treatment of fatty liver disease, and more particularly, to a method of administering a cyclohexenone compound.
- Fatty liver refers to a pathogenic condition where fat comprises more than 5% of the total weight of the liver. Fatty liver and steatohepatitis are frequently found in people who intake excessive alcohols and who have obesity, diabetes, hyperlipidemia, etc. Nonalcoholic fatty liver disease (NAFLD) refers to a wide spectrum of liver disease ranging from simple fatty liver (steatosis), to nonalcoholic steatohepatitis (NASH), to cirrhosis (irreversible, advanced scarring of the liver). All of the stages of NAFLD have in common the accumulation of fat (fatty infiltration) in the liver cells (hepatocytes). In NASH, the fat accumulation is associated with varying degrees of inflammation (hepatitis) and scarring (fibrosis) of the liver. The NAFLD spectrum is thought to begin with and progress from its simplest stage, called simple fatty liver (steatosis). That is, fatty liver is the initial abnormality in the spectrum of NAFLD. Simple fatty liver involves just the accumulation of fat in the liver cells with no inflammation or scarring. The fat is actually composed of a particular type of fat (triglyceride) that accumulates within the liver cells. Fatty liver is a harmless (benign) condition. The next stage and degree of severity in the NAFLD spectrum is NASH. As mentioned, NASH involves the accumulation of fat in the liver cells as well as inflammation of the liver. The inflammatory cells can destroy the liver cells (hepatocellular necrosis). In the terms “steatohepatitis” and “steatonecrosis”, steato refers to fatty infiltration, hepatitis refers to inflammation in the liver, and necrosis refers to destroyed liver cells. Strong evidence suggests that NASH, in contrast to simple fatty liver, is not a harmless condition. This means that NASH can ultimately lead to scarring of the liver (fibrosis) and then irreversible, advanced scarring (cirrhosis). Cirrhosis that is caused by NASH is the last and most severe stage in the NAFLD spectrum.
- There are few therapeutically effective drugs for treating fatty liver. Exercise and controlled diet are recommended, but these are not so effective in treating fatty liver.
- Accordingly, development of a fatty liver treatment having superior effect and safety with no adverse reactions is in need.
- The invention provides a method of treating, inhibiting and/or preventing fatty liver disease in a patient in need thereof, comprising administering an effective amount of a cyclohexenone compound of the formula (I) as described herein to said patient. In an exemplary embodiment, the cyclohexenone compound is administered with a second ingredient.
- In one aspect provides methods of treating, inhibiting and/or preventing fatty liver disease in a patient in need thereof, comprising administering an effective amount of a cyclohexenone compound of the following formula (I) to said patient,
-
- wherein each of X and Y independently is oxygen, NR5 or sulfur;
- R is a hydrogen or C(═O)C1-C8alkyl;
- each of R1, R2 and R3 independently is a hydrogen, methyl or (CH2)mCH3;
- R4 is NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, halogen, 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, glucosyl, wherein the 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, and glucosyl are optionally substituted with one or more substituents selected from NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, and C1-C8 haloalkyl;
- each of R5 and R6 is independently a hydrogen or C1-C8alkyl;
- R7 is a C1-C8alkyl, OR5 or NR5R6;
- m=1-12; and
- n=1-12; or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof.
- All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
-
FIG. 1 (A-D) shows representative photomicrographs of HE-stained sections of livers of Group A (vehicle control) and Group B (test compound, Compound 1) in a Fatty Liver - Disease model.
FIG. 1(A) and 1(B) show HE-stained sections of livers of Group A at an enlargement ratio of 50× enlargement ratio of 200×, respectively.FIGS. 1(C) and 1(D) show HE-stained sections of livers of Group B at an enlargement ratio of 50 X enlargement ratio of 200×. -
FIG. 2 (A-D) shows representative photomicrographs of Sirius-red stained sections of livers of Group A and Group B Fatty Liver Disease model.FIGS. 2(A) and 2(B) show Sirius-red stained sections of livers of Group A at an enlargement ratio of 50× enlargement ratio of 200×, respectively.FIGS. 2(C) and 2(D) show Sirius-red stained sections of livers of Group B at an enlargement ratio of 50× enlargement ratio of 200×. -
FIG. 3 (A-D) shows representative photomicrographs of collagen Type 3-immunostained sections of livers of Group A and Group B Fatty Liver Disease model.FIGS. 3(A) and 3(B) show collagen Type 3-immunostained sections of livers of Group A at an enlargement ratio of 50× enlargement ratio of 400×, respectively.FIGS. 3(C) and 3(D) show Sirius-red stained sections of livers of Group B at an enlargement ratio of 50× enlargement ratio of 400×. -
FIG. 4 shows diagrams of the whole blood glucose concentration (mg/dL) of Group A and Group B. -
FIG. 5 shows diagrams of the plasma triglyceride concentration (mg/dL) of Group A and Group B. -
FIG. 6 andFIG. 7 respectively show diagrams of plasma AST and plasma ALT concentration (U/dL) of Group A and Group B. -
FIG. 8 (A-D) shows representative photomicrographs of HE-stained sections of livers of Group A and Group B regarding fibrosis of steatohepatitis liver cells.FIGS. 8(A) and 8(B) show HE-stained sections of livers of Group A at an enlargement ratio of 50× enlargement ratio of 200×, respectively.FIGS. 8(C) and 8(D) show HE-stained sections of livers of Group B at an enlargement ratio of 50× enlargement ratio of 200×. -
FIG. 9 (A-D) shows representative photomicrographs of Sirius-red stained sections of livers of Group A and Group B regarding fibrosis of steatohepatitis liver cells.FIGS. 9(A) and 9(B) show Sirius-red stained sections of livers of Group A at an enlargement ratio of 50× enlargement ratio of 200×, respectively.FIGS. 9(C) and 9(D) show Sirius-red stained sections of livers of Group B at an enlargement ratio of 50× enlargement ratio of 200×. -
FIG. 10 (A-D) shows representative photomicrographs of collagen Type 3-immunostained sections of livers of Group A and Group B regarding fibrosis of steatohepatitis liver cells.FIGS. 10(A) and 10(B) show collagen Type 3-immunostained sections of livers of Group A at an enlargement ratio of 50× enlargement ratio of 400×, respectively.FIGS. 10(C) and 10(D) show Sirius-red stained sections of livers of Group B at an enlargement ratio of 50× enlargement ratio of 400×. -
FIG. 11 shows diagrams of the whole blood glucose concentration (mg/dL) of Group A and Group B. -
FIG. 12 shows diagrams of the plasma triglyceride concentration (mg/dL) of Group A and Group B. -
FIG. 13 andFIG. 14 respectively show diagrams of plasma AST and plasma ALT concentration (U/dL) of Group A and Group B. -
FIG. 15 (A-F) shows representative photomicrographs of HE-stained sections of livers in a fatty liver condition assay in Group A (vehicle control), Group B (test compound & ergosterol) and Group C (test compound alone).FIGS. 15(A) and 15(B) show HE-stained sections of livers of Group A at an enlargement ratio of 50× enlargement ratio of 200×, respectively.FIGS. 15(C) and 15(D) show HE-stained sections of livers of Group B at an enlargement ratio of 50× enlargement ratio of 200×.FIGS. 15(E) and 15(F) show HE-stained sections of livers of Group C at an enlargement ratio of 50× enlargement ratio of 200×. -
FIG. 16 (A-F) shows representative photomicrographs of Sirius-red stained of livers from Group A to Group C.FIGS. 16(A) and 16(B) show Sirius-red stained sections of livers of Group A at an enlargement ratio of 50× enlargement ratio of 200×, respectively.FIGS. 16(C) and 16(D) show Sirius-red stained sections of livers of Group B at an enlargement ratio of 50× enlargement ratio of 200×.FIGS. 16(E) and 16(F) show Sirius-red stained sections of livers of Group C at an enlargement ratio of 50× enlargement ratio of 200×. -
FIG. 17 (A-F) shows representative photomicrographs of collagen Type 3-immunostained sections of livers from Group A to Group C.FIGS. 17(A) and 17(B) show collagen Type 3-immunostained sections of livers of Group A at an enlargement ratio of 50× enlargement ratio of 400×, respectively.FIGS. 17(C) and 17(D) show Sirius-red stained sections of livers of Group B at an enlargement ratio of 50× enlargement ratio of 400×.FIGS. 17(E) and 17(E) show Sirius-red stained sections of livers of Group C at an enlargement ratio of 50× enlargement ratio of 400×. - In some embodiments, the invention surprisingly found that cyclohexenone compounds described herein effectively treat, inhibit and/or prevent fatty liver disease.
- The terms “a” and “an” refer to one or to more than one (i.e., to at least one) of the grammatical object of the article.
- The term “treat,” “treatment” or “treating” means reducing the frequency, extent, severity and/or duration with which symptoms of fatty liver disease are experienced by a patient.
- The term “prevent,” “prevention” or “preventing” means inhibition, risk reduction, reducing the onset of or the averting of symptoms associated with fatty liver disease.
- The term “pharmaceutically acceptable salt” refers to those salts which retain the biological effectiveness and properties of the free bases and which are obtained by reaction with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, malic acid, maleic acid, succinic acid, tartaric acid, citric acid, and the like.
- The term “effective amount” means an amount of the compound described herein effective to treat, inhibit and/or prevent fatty liver diseases. For example, the effective amount of the compound described herein reduces the number of fat cells; reduces the liver size; inhibits (i.e., slow to some extent and preferably stop) fatty cell infiltration; inhibits (i.e., slows at least to some extent and preferably stops) inflammation (hepatitis), scarring (cirrhosis) or necrosis; and/or relieves to some extent one or more of the symptoms associated with the disease.
- Plants and mushrooms are a valuable resource for the discovery and development of novel, naturally derived agents to treat cancer. Antrodia camphorata is also called Chang-Zhi, Niu Chang-Gu, red camphor mushroom and the like, which is a perennial mushroom belonging to the order Aphyllophorales, the family Polyporaceae. It is an endemic species in Taiwan growing on the inner rotten heart wood wall of Cinnamomum kanehirae Hay. C. kanehirai Hay is rarely distributed and being overcut unlawfully, which makes A. camphorata growing inside the tree in the wild became even rare. The price of A. camphorata is very expensive due to the extremely slow growth rate of natural A. camphorata that only grows between Junes to October. Traditionally, A. camphorata is used as a Chinese remedy for food, alcohol, and drug intoxication, diarrhea, abdominal pain, hypertension, skin itches, and liver cancer. Triterpenoids are the most studied component among the numerous compositions of A. camphorata.
- U.S. Pat. No. 7,385,088 is directed to a novel compound and use thereof, in particular to Antroquinonol B and Antroquinonol C isolated from A. camphorata extracts which effectively inhibit the growth of certain cancer cells. U.S. Pat. No. 7,342,137 provides cyclohexenone compounds and their uses in tumor growth inhibition, which is an extract isolated and purified from A. camphorate, in particular to 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone. Furthermore, several uses of the compound, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone were developed. U.S. Pat. No. 7,411,003 discloses the use of 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone in inhibiting HBV. U.S. Pat. No. 7,456,225 discloses the use of 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone in liver protection such as alleviating liver injury and fibrosis induced by chemicals and reduces the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). U.S. Pat. No. 7,468,392 discloses the use of 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6-10-trienyl)-cyclohex-2-enone in delaying fatigue. U.S. Pat. No. 7,501,454 relates to the use of 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl-)-cyclohex-2-enone in treating autoimmune diseases. US 8,236,860 provides the use of 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone in inhibiting the survival of pancreatic cancer cells. US 20110060055, US 20110060056, US 20110060057, US 20110060058 and US 20110060059 disclose the use of 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl-)-cyclohex-2-enone in inhibiting the survival of lymphoma, gastric cancer, skin cancer, ovarian cancer and bladder cancer cells, respectively.
- However, none of prior references teaches and suggests that the above-mentioned cyclohexenone compound can be used in the treatment and/or prevention of fatty liver diseases, in particular NAFLD.
- Accordingly, the invention provides a method of treating, inhibiting and/or preventing fatty liver diseases in a patient in need thereof, comprising administering an effective amount of a cyclohexenone compound of the following formula (I) to said patient,
- wherein each of X and Y independently is oxygen, NR5 or sulfur;
R is a hydrogen or C(═O)C1-C8alkyl;
each of R1, R2 and R3 independently is a hydrogen, methyl or (CH2)m—CH3;
R4 is NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, halogen, 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, glucosyl, wherein the 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, and glucosyl are optionally substituted with one or more substituents selected from NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, and C1-C8 haloalkyl;
each of R5 and R6 is independently a hydrogen or C1-C8alkyl;
R7 is a C1-C8alkyl, OR5 or NR5R6;
m=1-12; and
n=1-12; or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof. - In some embodiments, the fatty liver diseases are the primary fatty liver diseases or the secondary fatty liver diseases. In some embodiments, the secondary fatty liver disease is alcohol liver disease, fatty liver associated with chronic hepatitis infection, total parental nutrition (TPN), Reye's Syndrome, gastrointestinal disorders, or gastroparesis and irritable bowel (IBS) disorders. In certain embodiments, the fatty liver disease is cirrhosis or fibrosis.
- In some embodiments, the cyclohexenone compound having the following structure
- is prepared synthetically or semi-synthetically from any suitable starting material. In other embodiments, the cyclohexenone compound is prepared by fermentation, or the like. For example, Compound 1 (also known as Antroquinonol™ or “Antroq”) or Compound 3, in some instances, is prepared from 4-hydroxy-2,3-dimethoxy-6-methylcyclohexa-2,5-dienone. The non-limited exemplary compounds are illustrated below.
- In other embodiments, the cyclohexenone compound having the structure
- is isolated from the organic solvent extracts of A. camphorata. In some embodiments, the organic solvent is selected from alcohols (e.g., methanol, ethanol, propanol, or the like), esters (e.g., methyl acetate, ethyl acetate, or the like), alkanes (e.g., pentane, hexane, heptane, or the like), halogenated alkanes (e.g., chloromethane, chloroethane, chloroform, methylene chloride, or the like), and the like. For example, exemplary Compounds 1-7 are isolated from organic solvent extracts. In certain embodiments, the organic solvent is alcohol. In certain embodiments, the alcohol is ethanol. In some embodiments, the cyclohexenone compound is isolated from the aqueous extracts of A. camphorata.
- In some embodiments, R is a hydrogen, C(═O)C3H8, C(═O)C2H5, or C(═O)CH3. In some embodiments, R1 is a hydrogen or methyl. In certain embodiments, R2 is a hydrogen, methyl, ethyl, propyl, butyl, pentyl or hexyl. In some embodiments, R3 is a hydrogen, methyl, ethyl, propyl, butyl, pentyl or hexyl. In some embodiments, R4 is halogen, NH2, NHCH3, N(CH3)2, OCH3, OC2H5, C(═O)CH3, C(═O)C2H5, C(═O)OCH3, C(═O)OC2H5, C(═O)NHCH3, C(═O)NHC2H5, C(═O)NH2, OC(═O)CH3, OC(═O)C2H5, OC(═O)OCH3, OC(═O)OC2H5, OC(═O)NHCH3, OC(═O)NHC2H5, or OC(═O)NH2. In some embodiments, R4 is C2H5C(CH3)2OH, C2H5C(CH3)2OCH3, CH2COOH, C2H5COOH, CH2OH, C2H5OH, CH2Ph, C2H5Ph, CH2CH═C(CH3)(CHO), CH2CH═C(CH3)(C(═O)CH3), 5 or 6-membered lactone, C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, and glucosyl, wherein the 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, and glucosyl are optionally substituted with one or more substituents selected from NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, and C1-C8 haloalkyl. In certain embodiments, R4 is CH2CH═C(CH3)2. In certain embodiments, the compound is
- According to the invention, in some embodiments, the compounds provided herein are used in the treatment, inhibition and/or prevention of fatty liver disease. Examples of fatty liver diseases or liver disorders include the primary fatty liver diseases NAFLD and NASH and the secondary fatty liver diseases (e.g., alcoholic liver disease (ALD), fatty liver associated with chronic hepatitis infection, total parental nutrition (TPN), Reye's Syndrome, and gastrointestinal disorders such as Intestinal Bacterial Overgrowth (IBO), gastroparesis, irritable bowel (IBS) disorders, and the like). These examples are listed as examples only and the list is not intended to limit the treatment to these diseases.
- In some embodiments, therapeutically-effective dosages vary when the drugs are used in treatment combinations. Combination treatment further includes periodic treatments that start and stop at various times to assist with the clinical management of the patient. For combination therapies described herein, dosages of the co-administered compounds vary depending on the type of co-drug employed, on the specific drug employed, on the disease, disorder, or condition being treated and so forth.
- It is understood that in some embodiments, the dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is sought, is modified in accordance with a variety of factors. These factors include the disorder from which the subject suffers, as well as the age, weight, sex, diet, and medical condition of the subject. Thus, in other embodiments, the dosage regimen actually employed varies widely and therefore deviates from the dosage regimens set forth herein.
- Combinations of compounds (i.e., the cyclohexenone compound described herein) with other fatty liver disease therapeutic agents are intended to be covered. In some embodiments, examples of fatty liver disease therapeutic agents include, but are not limited to, the following: ergosterol, vitamin E, selenium, betaine, insulin sensitizers (e.g., Metformin, Pioglitazone, Rosiglitazone, Thiazolidinediones, or the like), and statins, or the like.
- The combinations of the cyclohexenone compounds and other fatty liver disease therapeutic agents described herein encompass additional therapies and treatment regimens with other agents in some embodiments. Such additional therapies and treatment regimens include another fatty liver disease therapy in some embodiments. Alternatively, in other embodiments, additional therapies and treatment regimens include other agents used to treat adjunct conditions associated with fatty liver disease or a side effect from such agent in the combination therapy. In further embodiments, adjuvants or enhancers are administered with a combination therapy described herein.
- In some embodiment, the cyclohexenone compound of the invention is administered with a second ingredient. According to the invention, the second ingredient is ergosterol. The amounts of the cyclohexenone compound in combination with ergosterol range from 50% (w/w) to 90% (w/w) and 50% (w/w) to 10% (w/w), respectively. In general, the compositions described herein and, in embodiments where combinational therapy is employed based on the mode of action described herein, other agents do not have to be administered in the same pharmaceutical composition, and in some embodiments, because of different physical and chemical characteristics, are administered by different routes. In some embodiments, the initial administration is made according to established protocols, and then, based upon the observed effects, the dosage, modes of administration and times of administration is modified by the skilled clinician.
- In some embodiments, the compounds provided herein are administered by any convenient route, including oral, parenteral, subcutaneous, intravenous, intramuscular, intra peritoneal, or transdermal. The dosage administered depends upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, and the nature of the effect desired.
- In some embodiments, for administration, the compounds provided herein are mixed with one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations which are used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- In some embodiments, for oral administration, the compounds provided herein are formulated as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the compound of the invention; as a powder or granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
- In some embodiments, for injection, the compounds provided herein are formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants, for example polyethylene glycol, are generally known in the art. In some embodiments, pharmaceutical compositions which are used orally, include push-fit capsules.
- For administration by inhalation, the molecules for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
- In the case of a pressurized aerosol, the dosage unit is determined by providing a valve to deliver a metered amount in some embodiments. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator, is formulated containing a powder mix of the polypeptide and a suitable powder base such as lactose or starch in some embodiments.
- The dose will be determined by the activity of the compound produced and the condition of the subject, as well as the body weight or surface area of the subject to be treated. The size of the dose and the dosing regiment also will be determined by the existence, nature, and extent of any adverse side effects that accompany the administration of a particular compound in a particular subject. In determining the effective amount of the compound to be administered, the physician needs to evaluate circulating plasma levels, toxicity, and progression of the disease.
- 100 g of mycelia, fruiting bodies or mixture of both from A. camphorata were placed into a flask. A proper amount of water and alcohol (70-100% alcohol solution) was added into the flask and were stirred at 20-25 degrees Celsius (° C.) for at least 1 hour. The solution was filtered through a filter and a 0.45 μm (micrometer) membrane and the filtrate was collected as the extract. The filtrate of A. camphorata was subjected to a High Performance Liquid chromatography (HPLC). The HPLC was performed using a RP18 column, methanol (A) and 0.1˜0.5% acetic acid (B) as the mobile phase, with gradient of 0˜10 min in 95%˜20% B, 10-20 min in 20%˜10% B, 20˜35 min in 10%˜10% B, 35-40 min in 10%˜95% B, at a flow rate of 1 ml/min. The effluent was monitored with a UV-visible detector.
- The fractions at 25˜30 min were collected and concentrated to yield
Compound 1, 4-hydroxy-2,3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone, a product with the appearance of light yellow oil. The molecular formula, molecular weight and melting point of 4-hydroxy-2,3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone are C24H38O4, 390, and 48° C. to 52° C., respectively. NMR spectra of the compound showed that 1H-NMR (CDCl3)δ(ppm)=1.51, 1.67, 1.71, 1.75, 1.94, 2.03, 2.07, 2.22, 2.25, 3.68, 4.05, 5.07, and 5.14; 13C-NMR (CDCl3) δ(ppm)=12.31, 16.1, 16.12, 17.67, 25.67, 26.44, 26.74, 27.00, 39.71, 39.81, 4.027, 43.34, 59.22, 60.59, 120.97, 123.84, 124.30, 131.32, 135.35, 135.92, 138.05, 160.45, and 197.12. - The fractions collected at 21.2 to 21.4 min were collected and concentrated to yield compound 5, a product of pale yellow liquid. Compound 5 was analyzed to be 4-hydroxy-5-(11-hydroxy-3,7,11-trimethyldodeca-2,6-dienyl)-2,3-dimethoxy-6-methylcyclohex-2-enone with molecular weight of 408 (Molecular formula: C24 H40O5). 1H-NMR (CDCl3) δ (ppm)=1.21, 1.36, 1.67, 1.71, 1.75, 1.94, 2.03, 2.07, 2.22, 2.25, 3.68, 4.05, 5.71 and 5.56. 13C-NMR(CDCl3)δ(ppm): 12.31, 16.1, 16.12, 17.67, 25.67, 26.44, 26.74, 27.00, 30.10, 40.27, 43.34, 59.22, 60.59, 71.8, 120.97, 123.84, 124.30, 131.32, 134.61, 135.92, 138.05, 160.45, and 197.11.
- The fractions collected at 23.7 to 24.0 min were collected and concentrated to yield compound 7, a product of pale yellow liquid. Compound 7 was analyzed to be 4-hydroxy-2,3-dimethoxy-5-(11-methoxy-3,7,11-trimethyldodeca-2,6-dienyl)-6-methylcyclohex-2-enone with molecular weight of 422 (C25H42O5). 1H-NMR (CDCl3) δ (ppm)=1.21, 1.36, 1.71, 1.75, 1.94, 2.03, 2.07, 2.22, 2.25, 3.24, 3.68, 4.05, 5.12, 5.50, and 5.61. 13C-NMR(CDCl3)δ(ppm): 12.31, 16.1, 16.12, 17.67, 24.44, 26.44, 26.74, 27.00, 37.81, 39.81, 40.27, 43.34, 49.00, 59.22, 60.59, 120.97, 123.84, 124.30, 135.92, 138.05, 160.45 and 197.12.
- Compound 6, a metabolite of
Compound 1, was obtained from urine samples of rats fed withCompound 1 in the animal study. Compound 6 was determined to be 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3-methyl-2-hexenoic acid)cyclohex-2-enone with molecular weight of 312 (C16 H24 O6). Compound 4 which was determined as 3,4-dihydroxy-2-methoxy-6-methyl-5-(3,7,11-trimethyldodeca-2,6,10-trienyl)cyclohex-2-enone (molecular weight of 376, C23H36O4), was obtained whenCompound 1 was under the condition of above 40 ° C. for 6 hours. - Alternatively, the exemplary compounds may be prepared from 4-hydroxy-2,3-dimethoxy-6-methylcyclohexa-2,5-dienone, or the like.
- Similarly, other cyclohexenone compounds having the structure
- are isolated from Antrodia camphorata or prepared synthetically or semi-synthetically from the suitable starting materials. An ordinary person skilled in the art would readily utilize appropriate conditions for such synthesis.
- In order to simulate an unhealthy diet tendency in humans, such as excess consumption of high caloric food, the example constructs an animal model using rats fed a high fat diet to evaluate the effects of chronic liver injury. Thereafter, the effects can be revealed through biochemical assays to prove the fatty liver reduction of exemplary compounds provided herein such as
Compound 1, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6-10-trienyl)-cyclohex-2-enone (the test compound). - The assay simulates liver disease caused by a high fat diet through a “Metabolic Syndrome” model. That is, the model is different from conventional chemical induced models caused by toxic components such as CCl4. This model is distinguishable from the models caused by virus or alcohol.
- The establishment of a long term high-fat diet is described as follows: First, the C57BL/6 mice were obtained from Charles River Laboratories Japan (Kanagawa, Japan). Animals were housed under specific-pathogen-free (SPF) conditions. The liver injury was developed in 18 male mice by subcutaneous injection of Streptozotocin (STZ) 2 days after birth (day 2). After 4 weeks, a high-fat commercial rodent diet ad libitum (CLEA JAPAN) were supplied. These mice were randomized into 3 groups before the treatment. The test compound was administered in a volume of 10 ml/kg twice a day for three weeks. In the control group (group A), six rats were fed with vehicle (corn oil from Sigma Chemical Co.) via intubation. Six mice in group B were orally administered vehicle and the test compound at a dose of 48 mg/kg twice a day (96 mg/kg per day). Table 1 summarizes the study timetable.
-
TABLE 1 The timetable of the study Time Process Day 0 Birth Day 2 STZ treatment Day 28 Feeding high fat diet Day 62 Randomization Day 63-Day 76 Test compound administration Day 77 Sacrifice - Table 2 summarizes the treatment schedule.
-
TABLE 2 Experimental groups with the substances and dosages fed No. Dosage Volume Group mice Test substance (mg/kg) (ml/kg) Regiments A 6 Vehicle control — 10 Oral, twice a day, 9-11 weeks B 6 The test 48 compound - (1) HE Staining. The HE staining method is performed as follows: Liver slices are cut from the livers' left side, embedded in Tissue-Tek® OCT™ Compounds (Sakura Finetek, Japan), snap frozen in liquid nitrogen, and stored at −80° C. 5 μm sections are cut, air-dried, fixed in acetone, air dried again and finally washed with phosphate buffered saline (PBS). Then, in the hematoxylin and eosin staining method, liver sections will be prefixed in a Bouin solution (formalin-acetic acid) for one week and then stained with Lillie-Mayer's Hematoxylin (Muto Pure Chemicals, Japan) and eosin solution (Wako, Japan) to visualize the lipid deposition, inflammations, cell necrosis and fibrosis, or stained with Masson's trichromic solution to visualize extra cellular matrix and collagen fibers of liver fibrosis development.
- (2) Sirius Red Staining. The Sirius Red staining method is performed as follows: Liver slices are cut from the livers' left side, embedded in Tissue-Tek® OCT™ Compounds (Sakura Finetek, Japan), snap frozen in liquid nitrogen, and stored at −80° C. 5 μm sections are cut, air-dried, fixed in acetone, air dried again and finally washed with phosphate buffered saline (PBS). Then, liver sections are stained with a Picro-Sirius Red Solution (Waldeck GmbH & KG, Germany) to observe collagen deposition.
- (3) Immunohistochemistry of Collagen Type 3. The immunohistochemistry assay for collagen Type 3 is performed as follows: Liver slices are cut from the livers' left side, embedded in Tissue-Tek® OCT™ Compounds (Sakura Finetek, Japan), snap frozen in liquid nitrogen, and stored at −80° C. 5 μm sections are cut, air-dried, fixed in acetone, air dried again and finally washed with phosphate buffered saline (PBS). For immunohistochemistry, endogenous peroxidase activity will be blocked by using 0.03% H2O2 for 5 minutes, followed by incubation with Block Ace (Dainippon Sumitomo Pharm, Japan) for 10 minutes. The sections will be incubated with the optimal dilution of anti-Type 3 collagen antibody overnight at 4° C. After incubation with an appropriate secondary antibody, the substrate reactions are performed using DAB/
H 202 solution (Nichirei, Japan). - (1) Whole Blood Glucose. Blood samples were collected in heparinized syringes (Novo-Heparin 5,000 units/5 ml, Mochida Pharmaceutical, Japan) by cardiac puncture, kept on ice and centrifuged at 1,000×g at 4° C. for 15 minutes. The supernatant was collected and stored at −80° C. until use. Blood glucose was measured in whole blood samples using G Checker (Sanko Junyaku Co. Ltd., Japan).
- (2) Plasma Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT). The detection of plasma AST and ALT are performed as follows: Blood samples were collected in heparinized syringes (Novo-Heparin 5,000 units/5 ml, Mochida Pharmaceutical, Japan) by cardiac puncture and kept on ice then centrifuged at 1,000×g at 4° C. for 15 minutes. The supernatant was collected and stored at −80° C. until use. AST, ALT levels were measured by FUJI DRY CHEM 7000 (Fuji Film, Japan).
-
FIG. 1 toFIG. 7 have proved that the exemplary compound extracted from A. camphorata (Compound 1) effectively decreases the extent of fatty liver disease caused by non-chemical injury. The decrease is assessed by evaluating the extent of liver injuries of fat deposition by histological analyses such as HE staining, Sirius red staining and collagen immunostaining, and further by plasma biochemical marker such as blood glucose, plasma triglyceride, plasma ALT and plasma AST. - HE staining reveals the morphology of hepatic cells under inflammatory cell infiltration, and macro- and micro- vesicular fat deposition.
FIG. 1 (A-D) shows the representative photomicrographs of HE-stained sections of livers of Group A and Group B, whereinFIG. 1(A) and 1(C) show an enlargement ratio of 50× andFIGS. 1(B) and 1(D) show an enlargement ratio of 200×. As shown inFIGS. 1(A) and 1(B) , the Group A (vehicle) diagrams revealed infiltration of inflammatory cells, macro- and micro vesicular fat deposition, proliferated bile ducts and hepato-cellular ballooning in the liver sections. As shown in FIGS. 1(C) and 1(D), group B (the test compound, Compound 1) treatment tended to decrease the infiltration of inflammatory cells and also tended to decrease the macro-vesicular fat deposition compared to Group A. - Sirius Red Staining is utilized to detect collagen deposition.
FIG. 2 shows the representative photomicrographs of Sirius-red staining of livers of Group A and Group B, whereinFIGS. 2(A) and 2(C) show an enlargement ratio of 50× andFIGS. 2(B) and 2(D) show an enlargement ratio of 200×. As shown inFIGS. 2(A) and 2(B) , in group A, Sirius red staining demonstrates collagen deposition around central veins, bile ducts and degenerative hepatocytes. As shown inFIGS. 2(C) and 2(D) , in Group B (the test compound, Compound 1) treatment, the collagen deposition around the central veins and the bile ducts was reduced. - Collagen Type 3 staining is used to detect the distribution of collagen fibers.
FIG. 3 shows the representative photomicrographs of collagen Type 3-immunostained sections of livers of Group A and Group B, whereinFIGS. 3(A) and 3(C) show an enlargement ratio of 50× andFIGS. 3(B) and 3(D) show an enlargement ratio of 400×. As shown inFIGS. 3(A) and 3(B) , Collagen Type 3 staining shows accumulation of collagen fibers in the sinusoidal area and around bile ducts and central veins in the Vehicle control group A. As shown inFIGS. 3(C) and 3(D) , the Group B (the test compound, Compound 1) treatment tended to reduce the thickness and/or the length of the collagen fibers in the sinusoidal area. -
FIG. 4 shows the diagram of the whole blood glucose concentration (mg/dL) of Group A and Group B. As shown inFIG. 4 , Group B treatment (the test compound, Compound 1) showed a decrease in the whole blood glucose level compared to the results of Group A treatment (Group A: 636±137 mg/dL, Group B: 580±122 mg/dL). -
FIG. 5 shows the diagram of the plasma triglyceride (TG) concentration (mg/dL) of Group A and Group B. As shown inFIG. 5 , Group B treatment (the test compound, Compound 1) showed a significant decrease in the plasma TG compared to the results of Group A treatment (Group A: 643±402 mg/dL, Group B: 229±144 mg/dL). - The aspartate aminotransferase (AST) and the alanine aminotransferase (ALT) are important enzymes in the amino acid synthesis for the human organs such as liver, heart, muscles, etc. AST and ALT are commonly measured clinically as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. These enzymes' content in serum is low under normal conditions. Significantly elevated levels of AST and ALT often suggest the existence of liver injury.
FIG. 6 andFIG. 7 show diagrams of plasma AST and plasma ALT concentration (U/dL) for Group A and Group B, respectively. As shown inFIG. 6 , Group B (the test compound, Compound 1) treatment seems to slightly reduce the plasma AST level compared to Group A (vehicle) treatment (Group A: 202±177 U/L, Group B: 141±35 U/L). As shown inFIG. 7 , Group B (the test compound, Compound 1) treatment seems to slightly reduce the plasma ALT level compared to Group A (vehicle) treatment (Group A: 64±64 U/L, Group B: 34±10 U/L). - In summary, the test compound treatment decreased the plasma TG levels, tending to inhibit blood glucose levels, and slightly decreased the plasma AST and ALT. The test compound treatment also decreased the infiltration of inflammatory cells and fat deposition in the liver lobule. Moreover, the test compound tended to inhibit collagen deposition, shown in both Sirius red staining and collagen Type 3 staining, suggesting that the test compound has an anti-fibrotic effect on liver fibrosis steatohepatitis.
-
FIG. 8 toFIG. 14 show that the test compound,Compound 1 effectively decrease fibrosis of steatohepatitis liver cells induced by non-chemical injury. The decrease is assessed by evaluating the extent of liver injuries in liver fibrosis by histological analyses such as HE staining, Sirius red staining and collagen immunostaining, and further by plasma biochemical marker such as blood glucose, plasma alanine aminotransferase and plasma aspartate aminotransferase. -
FIG. 8 shows the representative photomicrographs of HE-stained sections of livers of Group A and Group B, whereinFIGS. 8(A) and 8(C) show an enlargement ratio of 50×, andFIGS. 8(B) and 8(D) show an enlargement ratio of 200×. As shown inFIGS. 8(A) and 8(B) , the Group A (vehicle) diagrams reveal infiltration of inflammatory cells, macro- and micro vesicular fat deposition, proliferated bile ducts, and hepatocellular ballooning in the liver sections. As shown inFIGS. 8(C) and 8(D) , group B (the test compound, Compound 1) treatment tended to decrease the macro-vesicular fat deposition compared to Group A. -
FIG. 9 shows the representative photomicrographs of Sirius-red staining of livers of Group A and Group B, whereinFIGS. 9(A) and 9(C) show an enlargement ratio of 50×, andFIGS. 9(B) and 9(D) show an enlargement ratio of 200×. As shown inFIGS. 9(A) and 9(B) , in Group A, Sirius red staining demonstrates collagen deposition around central veins, bile ducts and degenerative hepatocytes. In Group A treatment, central-to-central bridging fibrosis is observed, showing serious fibrosis in liver cells. As shown inFIGS. 9(C) and 9(D) , in Group B (the test compound, Compound 1) treatment, the collagen deposition around the central veins and the bile ducts was reduced. -
FIG. 10 shows the representative photomicrographs of collagen Type 3-immunostained sections of livers of Group A and Group B, whereinFIGS. 10(A) and 10(C) show an enlargement ratio of 50×, andFIGS. 10(B) and 10(D) show an enlargement ratio of 400×. As shown inFIGS. 10(A) and 10(B) , Collagen Type 3 staining shows accumulation of collagen fibers in the sinusoidal area, and around bile ducts and central veins in the Vehicle control Group A. As shown inFIGS. 10(C) and 10(D) , the Group B (the test compound, Compound 1) treatment tended to reduce the thickness and/or the length of the collagen fibers in the sinusoidal area. -
FIG. 11 shows the diagram of the whole blood glucose concentration (mg/dL) of Group A and Group B. As shown inFIG. 11 , Group B treatment (the test compound, Compound 1) showed a significant decrease in the whole blood glucose level compared to the results of Group A treatment (Group A: 728±109 mg/dL, Group B: 566±65 mg/dL). -
FIG. 12 shows the diagram of the plasma triglyceride (TG) concentration (mg/dL) of Group A and Group B. As shown inFIG. 12 , Group B treatment (the test compound, Compound 1) showed a slight decrease in the plasma TG compared to the results of Group A treatment (Group A: 758±877 mg/dL, Group B: 704±450 mg/dL). -
FIG. 13 andFIG. 14 , respectively show diagrams of plasma AST and plasma ALT concentration (U/dL) for Group A and Group B. InFIG. 13 , Group B (the test compound, Compound 1) treatment slightly increase the plasma AST level compared to Group A (vehicle) treatment, but the change is not significant (Group A: 143±42 U/L, Group B: 167±87 U/L). As shown inFIG. 14 , Group B (the test compound, Compound 1) treatment reduces the plasma ALT level compared to Group A (vehicle) treatment (Group A: 47±22 U/L, Group B: 38±11 U/L). - In summary, the treatment with the test compound (e.g., Compound 1) decreased the blood glucose levels, the plasma TG levels, and tends to decrease the fat deposition in the liver lobule and the ALT levels, suggesting that the cyclohexenone compounds provided herein have an ameliorating effect on lipid and carbohydrate metabolism and a protective effect on liver injury caused by a high-fat diet. Also, the exemplary cyclohexenone compound (e.g., Compound 1) tended to inhibit collagen deposition, shown in both Sims red staining and collagen Type 3 staining, showing that the cyclohexenone compounds provided herein have an anti-fibrotic effect on liver steatohepatitis.
- Taken together, the present invention successfully demonstrated that the test compound treatment effectively decrease the extents of fatty liver disease and liver fibrosis induced by metabolic syndrome, especially from high-fat diet treatment.
- Except for the testing groups and treatment schedule, the materials and processes of Metabolic Syndrome” model, Histology analysis, Whole blood and plasma biochemistry and Fatty Liver Disease Caused by Non-Chemical Injury are similar to those stated in Example 2.
- In control group (group A), six rats were fed with vehicle (corn oil from Sigma chemical co.) by means of stomach tubes. Six rats in group B were orally administered vehicle and the test compound (Compound 1) at a dose of 48 mg/kg twice a day (96 mg/kg per day) and ergosterol at a dose of 12 mg/kg twice a day (24 mg/kg per day). Six mice in group C were orally administered vehicle and the test compound (Compound 1) at a dose of 48 mg/kg twice a day (96 mg/kg per day).
- Table 1 below shows the study timetable summary.
-
TABLE 1 The timetable of the study Time Process Day 0 Birth Day 2 STZ treatment Day 28 Feeding high fat diet Day 62 Randomization Day 63-Day 76 Test substance administration Day 77 Sacrifice - Table 2 shows the treatment schedule.
-
TABLE 2 Experimental groups with the substances they were fed with and their dosages No. Dosage Volume Group mice Test substance (mg/kg) (ml/kg) Regiments A 6 Vehicle control — 10 Oral, twice a day, 9-11 weeks B 6 The test 48 compound Ergosterol 12 C 6 The test 48 compound -
FIG. 15 shows the representative photomicrographs of HE-stained sections of livers from Group A to Group C, whereinFIGS. 15(A), 15(C), 15(E) show an enlargement ratio of 50× andFIGS. 15(B), 15(D), 15(F) show an enlargement ratio of 200×. As shown inFIGS. 15(A) and 15(B) , the Group A figures revealed infiltration of inflammatory cells, macro- and micro vesicular fat deposition, proliferated bile ducts and hepatocellular ballooning in the liver sections. As shown inFIGS. 15(C) and 15(D) , treatment with combination of the test compound (Compound 1) and ergosterol decreased the macro vesicular fat deposition and the infiltration of inflammatory cells. The number of mitotic figures in hepatocytes is higher in group B compared to the group A. As shown inFIGS. 15(E) and 15(F) , the treatment with the test compound alone tended to decrease the macro vesicular fat deposition but did not affect the infiltration of inflammatory cells. - From
FIG. 15 , it is recognized that the treatment with the test compound (Compound 1) and ergosterol (Group B) have the ability of reducing the macro vesicular fat deposition. Compared to the treatment with the test compound alone (Group C), the treatment with the test compound and ergosterol (Group B) further inhibit the inflammatory cells infiltration, thereby showing better anti-inflammatory effects with respect to Group C. -
FIG. 16 shows the representative photomicrographs of Sirius-red stained of livers from Group A to Group C, whereinFIGS. 16(A), 16(C), 16(E) show an enlargement ratio of 50× andFIGS. 16(B), 16(D), 16(F) show an enlargement ratio of 200×. As shown inFIGS. 16(A) and 16(B) , in group A, Sirius red staining show collagen deposition around central veins, bile ducts and degenerative hepatocytes, showing central-to-central bridging fibrosis and indicating serious fibrosis steatohepatitis. As shown inFIGS. 16(C) and 16(D) , the treatment with the combination of the test compound (Compound 1) and ergosterol tended to decrease the collagen deposition. As shown inFIGS. 16(E) and 16(F) , the cyclohexenone alone treatment tended only slightly to decrease the collagen deposition compared to that in the control group. - In summary, both the treatments with the cyclohexeone compound provided herein (e.g., Compound 1) and ergosterol treatment (Group B) and the treatment with the test compound alone (Group C) tend to inhibit collagen deposition, and thus prevent liver fibrosis. More specifically, the treatment with the combination of the cyclohexenone compound provided herein (e.g., Compound 1) and ergosterol provides a better anti-liver-fibrosis ability compared to the treatment with the test compound alone.
-
FIG. 17 shows the representative photomicrographs of collagen Type 3-immunostained sections of livers from Group A to Group C, whereinFIGS. 17(A), 17(C), 17(E) show an enlargement ratio of 100× andFIGS. 17(B), 17(D), 17(F) show an enlargement ratio of 400×. As shown inFIGS. 17(A) and 17(B) , Collagen Type 3 staining shows accumulation of collagen fibers in the sinusoidal area and around bile ducts and central veins in the Vehicle control group. As shown inFIGS. 17(C), 17(D), 17(E) and 17(F) , the combination of cyclohexenone (e.g., Compound 1) and ergosterol treatment and the cyclohexenone alone treatment tended to reduce the collagen deposition proved by the decrease of the thickness of the collagen fibers in the sinusoidal area, indicating their anti-fibrosis ability. - The primary objectives of this study are to assess, in patients with Type 2 diabetes mellitus (DM) and presumed nonalcoholic fatty liver disease (NAFLD), the following:
- The safety and tolerability of multiple doses of
Compound 1; - The effects of 2 dose levels (50 mg and 100 mg) of
Compound 1 on insulin resistance and glucose homeostasis; - Effects of
Compound 1 on hepatocellular function as measured by assessment of liver enzymes and biochemical markers of hepatic and metabolic function and inflammation. - Study Type: Interventional
- Insulin Resistance and Glucose Homeostasis [Time Frame: baseline and 6 weeks] [Designated as safety issue: No]
- The primary objective of assessing changes in insulin resistance and glucose homeostasis will be attained by performing a euglycemic clamp procedure at baseline (Day 0) and at the end of 6 weeks of treatment (Day 43).
- Hepatocellular Function [Time Frame: baseline and 6 weeks] [Designated as safety issue: Yes]
- Hepatocellular function as measured by assessment of liver enzymes and biochemical markers of hepatic and metabolic function
-
Arms Assigned Interventions Active Comparator: Drug: Compound 150 mg Compound 150 mg by mouth once daily, 100 mg by mouth once daily Active Comparator: Drug: Compound 1100 mg Compound 1100 mg by mouth once daily, 200 mg by mouth once daily Placebo Comparator: Placebo Drug: Placebo Placebo - This is a multi-center, double-blind, randomized, placebo-controlled, multiple-dose, parallel-group study. Three (3) cohorts of 12 patients each will receive either placebo, 50
mg Compound mg Compound 1 by mouth daily for 6 weeks. - The primary objective of assessing changes in insulin resistance and glucose homeostasis will be attained by performing a euglycemic clamp procedure at baseline (Day 0) and at the end of 6 weeks of treatment (Day 43). Other endpoints will be evaluated by monitoring adverse experiences; vital signs; clinical laboratory values; plasma drug and metabolite concentrations; and general health and well-being.
- Ages Eligible for Study: 18 Years to 75 Years
- Type 2 diabetes, defined by the American Diabetes Association (ADA), as one of the following criteria:
- Symptoms of diabetes plus casual plasma glucose concentration >200 mg/dL (11.1 mmol/L) or Fasting plasma glucose >126 mg/dL (7.0 mmol/L) or 2-hour post-load glucose >200 mg/dL (11.1 mmol/L) during a 75 g oral glucose tolerance test (GTT).
- Presumed NAFLD, defined by one of the following criteria:
- Alanine aminotransferase (ALT) ≥47 U/L for females and ≥56 U/L for males
Aspartate aminotransferase (AST) ≥47 U/L for females and ≥60 U/L for males
Enlarged liver (demonstrated by ultrasound or other imaging technique)
Diagnostic histological findings shown on prior biopsy (in the last 5 years). - Bilirubin >2×ULN
- ALT >155 U/L for females and >185 U/L for males.
AST >155 U/L for females and >200 U/L for males.
Patients taking any antidiabetic medications, with the exception of metformin and sulfonylureas. If the HbA1c is <11%, patients may be enrolled who have been withdrawn from all other diabetic medications as specified in the protocol, at the discretion of the Principal Investigator. - To prepare a pharmaceutical composition for oral delivery, 100 mg of an
exemplary Compound 1 is mixed with 100 mg of corn oil. The mixture is incorporated into an oral dosage unit in a capsule, which is suitable for oral administration. - In some instances, 100 mg of a compound described herein is mixed with 750 mg of starch. The mixture is incorporated into an oral dosage unit for, such as a hard gelatin capsule, which is suitable for oral administration.
- To prepare a pharmaceutical composition for buccal delivery, such as a hard lozenge, mix 100 mg of a compound described herein, with 420 mg of powdered sugar mixed, with 1.6 mL of light corn syrup, 2.4 mL distilled water, and 0.42 mL mint extract. The mixture is gently blended and poured into a mold to form a lozenge suitable for buccal administration.
- To prepare a pharmaceutical composition for inhalation delivery, 20 mg of a compound described herein is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is incorporated into an inhalation delivery unit, such as a nebulizer, which is suitable for inhalation administration.
- While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/180,781 US20210177775A1 (en) | 2013-03-13 | 2021-02-20 | Method for the treatment of fatty liver disease |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/801,697 US20140274979A1 (en) | 2013-03-13 | 2013-03-13 | Method for the treatment of fatty liver disease |
US15/633,719 US20170304224A1 (en) | 2013-03-13 | 2017-06-26 | Method for the treatment of fatty liver disease |
US16/699,405 US10959963B2 (en) | 2013-03-13 | 2019-11-29 | Method for the treatment of fatty liver disease |
US17/180,781 US20210177775A1 (en) | 2013-03-13 | 2021-02-20 | Method for the treatment of fatty liver disease |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/699,405 Continuation US10959963B2 (en) | 2013-03-13 | 2019-11-29 | Method for the treatment of fatty liver disease |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210177775A1 true US20210177775A1 (en) | 2021-06-17 |
Family
ID=51529924
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/801,697 Abandoned US20140274979A1 (en) | 2013-03-13 | 2013-03-13 | Method for the treatment of fatty liver disease |
US15/633,719 Abandoned US20170304224A1 (en) | 2013-03-13 | 2017-06-26 | Method for the treatment of fatty liver disease |
US16/699,405 Active US10959963B2 (en) | 2013-03-13 | 2019-11-29 | Method for the treatment of fatty liver disease |
US17/180,781 Pending US20210177775A1 (en) | 2013-03-13 | 2021-02-20 | Method for the treatment of fatty liver disease |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/801,697 Abandoned US20140274979A1 (en) | 2013-03-13 | 2013-03-13 | Method for the treatment of fatty liver disease |
US15/633,719 Abandoned US20170304224A1 (en) | 2013-03-13 | 2017-06-26 | Method for the treatment of fatty liver disease |
US16/699,405 Active US10959963B2 (en) | 2013-03-13 | 2019-11-29 | Method for the treatment of fatty liver disease |
Country Status (12)
Country | Link |
---|---|
US (4) | US20140274979A1 (en) |
EP (1) | EP2968217B1 (en) |
JP (1) | JP6377713B2 (en) |
KR (1) | KR20150130352A (en) |
CN (1) | CN105209028B (en) |
BR (1) | BR112015022571A2 (en) |
ES (1) | ES2730739T3 (en) |
HK (1) | HK1216614A1 (en) |
MX (1) | MX2015012455A (en) |
SG (1) | SG11201507181YA (en) |
TW (1) | TWI631943B (en) |
WO (1) | WO2014158242A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018534323A (en) * | 2015-11-19 | 2018-11-22 | シニュー・ファーマ・インコーポレイテッドSiNew Pharma Inc. | Pharmaceutical composition for prevention or treatment of fatty liver |
CN107343890A (en) * | 2016-05-06 | 2017-11-14 | 北京大学 | The application of Antrodia camphorata and monomer lanostane 32 in NASH is prevented and treated |
MY194948A (en) * | 2016-05-13 | 2022-12-28 | Golden Biotechnology Corp | Methods and compositions for treating advanced stage non-small cell lung cancer |
EP3515492B1 (en) * | 2016-09-23 | 2023-07-26 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
AU2020229809A1 (en) * | 2019-02-25 | 2021-10-07 | Arjil Biotech Holding Company Limited | Method and composition for inhibiting virus infection |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2041077A2 (en) * | 2006-07-19 | 2009-04-01 | The Ohio State University Research Foundation | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
CN101516835A (en) * | 2006-07-19 | 2009-08-26 | 俄亥俄州立大学研究基金会 | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
JP2008260695A (en) * | 2007-04-10 | 2008-10-30 | Nissei Bio Kk | Hepatopathy inhibitor |
TWI394573B (en) * | 2007-06-14 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Liver Protection |
CN101785793A (en) * | 2009-01-23 | 2010-07-28 | 伟诚生物科技有限公司 | Application of antradiacomphora extract capsule for protecting liver and promoting body immune regulation function |
CA2798735A1 (en) * | 2010-05-19 | 2011-11-24 | Haruki Shibata | Prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis |
US8309611B2 (en) * | 2010-09-20 | 2012-11-13 | Golden Biotechnology Corporation | Methods and compositions for treating lung cancer |
-
2013
- 2013-03-13 US US13/801,697 patent/US20140274979A1/en not_active Abandoned
- 2013-11-26 BR BR112015022571A patent/BR112015022571A2/en not_active IP Right Cessation
- 2013-11-26 SG SG11201507181YA patent/SG11201507181YA/en unknown
- 2013-11-26 CN CN201380074591.0A patent/CN105209028B/en active Active
- 2013-11-26 JP JP2016500112A patent/JP6377713B2/en active Active
- 2013-11-26 EP EP13880440.6A patent/EP2968217B1/en active Active
- 2013-11-26 KR KR1020157027353A patent/KR20150130352A/en not_active Application Discontinuation
- 2013-11-26 MX MX2015012455A patent/MX2015012455A/en unknown
- 2013-11-26 ES ES13880440T patent/ES2730739T3/en active Active
- 2013-11-26 WO PCT/US2013/072092 patent/WO2014158242A1/en active Application Filing
-
2014
- 2014-01-09 TW TW103100845A patent/TWI631943B/en active
-
2016
- 2016-04-22 HK HK16104631.9A patent/HK1216614A1/en unknown
-
2017
- 2017-06-26 US US15/633,719 patent/US20170304224A1/en not_active Abandoned
-
2019
- 2019-11-29 US US16/699,405 patent/US10959963B2/en active Active
-
2021
- 2021-02-20 US US17/180,781 patent/US20210177775A1/en active Pending
Non-Patent Citations (1)
Title |
---|
Remington, The Science and Practice of Pharmacy, Nineteenth Edition-1995, page 710-712 * |
Also Published As
Publication number | Publication date |
---|---|
JP2016512238A (en) | 2016-04-25 |
EP2968217A4 (en) | 2016-11-02 |
ES2730739T3 (en) | 2019-11-12 |
SG11201507181YA (en) | 2015-10-29 |
US20170304224A1 (en) | 2017-10-26 |
CN105209028A (en) | 2015-12-30 |
WO2014158242A1 (en) | 2014-10-02 |
HK1216614A1 (en) | 2016-11-25 |
EP2968217B1 (en) | 2019-03-13 |
EP2968217A1 (en) | 2016-01-20 |
MX2015012455A (en) | 2016-04-07 |
TWI631943B (en) | 2018-08-11 |
US20200093757A1 (en) | 2020-03-26 |
CN105209028B (en) | 2019-06-14 |
TW201440759A (en) | 2014-11-01 |
US20140274979A1 (en) | 2014-09-18 |
BR112015022571A2 (en) | 2017-07-18 |
US10959963B2 (en) | 2021-03-30 |
JP6377713B2 (en) | 2018-08-22 |
KR20150130352A (en) | 2015-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10959963B2 (en) | Method for the treatment of fatty liver disease | |
US20130072459A1 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
US20210069192A1 (en) | Use of neutrophil elastase inhibitors in liver disease | |
US20230103774A1 (en) | Use of kaurane compounds in preparation of drug for prevention and treatment of sepsis and multiple organ damage | |
US20210128596A1 (en) | Compositions and methods for treating septic cardiomyopathy | |
SE1350211A1 (en) | Methods and compositions for the treatment of cancer metastases | |
US20130203861A1 (en) | Methods and compositions for treating ovarian cancer | |
TWI469784B (en) | Therapeutic compositoin for treating cancers | |
JP2017109987A (en) | Methods for treating diseases mediated by erbb4+ pro-inflammatory macrophages | |
US8206760B2 (en) | Composition for inhibition of transplant rejection containing the cordyceps mycellia extract as an active ingredient | |
CN114869870B (en) | Use of EPI-001 for preventing and/or treating nonalcoholic fatty liver disease | |
TWI797455B (en) | An use of antrodin compounds for preventing or treating non-alcoholic fatty liver disease | |
US9198922B2 (en) | Therapeutic composition for treating cancers | |
US20230190682A1 (en) | Pharmaceutical composition for preventing or treating metabolic diseases | |
KR20230008711A (en) | Methods and compositions for treating RNA virus induced diseases | |
KR20240099045A (en) | Pharmaceutical Composition for Preventing or Treating Non-alcoholic Fatty Liver Disease containing Sodium-Glucose Cotransporter-2 Inhibitor and Angiotensin Ⅱ Receptor Blocker | |
TW201503889A (en) | Use of eburicoic acid or derivative thereof in prevention or treatment of pain, inflammation and liver injury | |
TW202210073A (en) | Use of a composition containing antrocinol in manufacture of medicament for inhibiting growth of hepatoma cancer cells or hepatoma cancer stem cells | |
CN113041248A (en) | Application of Ravoxertinib in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease or hepatitis | |
CN113082033A (en) | Application of FR180204 in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease or hepatitis | |
US20150265644A1 (en) | Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds | |
CN115429799A (en) | Application of MAGL inhibitor in preparation of drugs for preventing or treating hepatitis | |
KR20120017498A (en) | A composition for athero-sclerosis comprising the polyphenol extracts from phellinus baumii | |
US20150265682A1 (en) | Therapeutic methods and compositions for treating diabetes | |
CA2847286A1 (en) | Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GOLDEN BIOTECHNOLOGY CORPORATION, TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIU, SHENG-YUNG;WEN, WU-CHE;CHEN, CHIH-MING;SIGNING DATES FROM 20130618 TO 20130621;REEL/FRAME:055502/0141 Owner name: GOLDEN BIOTECHNOLOGY CORPORATION, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GOLDEN BIOTECHNOLOGY CORPORATION;REEL/FRAME:055502/0138 Effective date: 20131122 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STCV | Information on status: appeal procedure |
Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER |
|
STCV | Information on status: appeal procedure |
Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED |